Get Adobe Flash player

ROLE OF CALPROTECTIN S100A8/S100A9 IN PATHOLOGICAL BIOMINERALIZATION

Аuthors: R. A. Moskalenko

Pages: 186–194

Abstract

         

Calprotectin has two calcium-binding proteins S100A8 (calgranulin A) and S100A9 (calgranulin B), which belong to the family of S100 proteins. These proteins are involved in intracellular signaling, affecting on the level of Ca2+ and as Ca2+ -buffer proteins. S100 proteins are involved in many cellular processes, such as cell cycle regulation, cell growth, differentiation and chemotaxis.
Today, metabolic disorders with S100 protein family are associated with development and progress of such pathologies as cardiomyopathy, atherosclerosis, neurodegenerative diseases, connective tissue diseases. Besides calprotectins take part in inflammation, reports about their antimicrobial activity, regulatory activity against cells, which are involved in immune reactions, carcinogenesis, development of amyloid-associated diseases are accumulated.
The aim is to analyze the data of scientific literature to establish the role of proteins calgranulins A and B and their complex (calprotectin) in the development of pathological biomineralization of soft tissues in human body.
Calprotectin is expressed by granulocytes, monocytes and macrophages in early stages of differentiation. For example, proteins S100A8 and S100A9 take up 45% of all cytoplasmic proteins in neutrophils, and in monocytes  only about 1% of protein cytoplasm. Also calprotectins expression was described in fibroblasts and endothelial cells, activated mature macrophages, osteoblasts and keratinocytes.
The main part of cytokino- and chemokino-like calprotectin activity is caused by its conection with RAGE receptors (receptor of advanced glycation and end products) and TLR4 (toll-like receptor 4) that trigger signaling pathways, which contribute to calcification in the vascular system, prostate, regulate cytoskeleton structure through polymerization of tubulin and more.
Calgranulin A (S100A8) and calgranulin B (S100A9) alone and as part of calprotectins complex are extremely interesting objects for stud-ing their possible role in the pathological process of biomineralization. In addition to chemokine and cytokine activity and influence on different specific receptors, these molecules have important constitutive feature: the binding of calcium and some other two valence ions. The combination of proteins S100A8 and S100A9 with biomineralization in such pathological processes as inflammation, tumor growth and atherosclerosis, says abot their obvious correlation.
Calprotectin-dependent endothelial damage may be a critical element in vascular morphogenesis biomineralization during chronic inflammation, atherosclerosis and cancer.
During analysis of the literature a concentration-dependent effect of S100A8/S100A9 on tumor cells is revealed: calprotectin and its components contribute to tumor growth and spread at low concentrations, at high concentrations – cause apoptosis of neoplastic cells. Besides, calprotectin affect directly tumor cells through interaction with TLR4, which are expressed in them and they are endogenous receptors for S100A8/S100A9.
The number of calgranulin A and B increases at the early stages of complicated atherosclerosis while the development of biomineralization. S100A8 and S100A9 in atherosclerotic plaque may significantly affect the redox and calcium-dependent processes of atherosclerosis pathogenesis and its chronic complications, including abnormal biomineralization. Numerous properties of calgranulin S100A8/S100A9 and its components can be a point of the promising new drugs and finding new biomarkers of disease.

Keywords: calprotectin, biomineralization, calgranulin A, calgranulin B, atherosclerosis.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Moore B. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun. 1965; 19:739-744.
  2. Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N. Identification of p 8, 14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. Journal of Biological Chemistry. 1991; 266 (12):7706-7713.
  3. Erchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity and cancer. J. Leukoc. Biol. 2009; 86:557-566.
  4. Altwegg L.A, Neidhart M, Hersberger M et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early and sensitive marker of acute coronary syndromes. Eur. Heart J. 2007; 28: 941-948.
  5. McCormick M, Rahimi F, Bobryshev Y.V, Gaus K [et al]. S100A8 and S100A9 in human arterial wall. The journal of biological chemistry. 2005; 280 (50):41521–41529.
  6. Healy AM, Pickard MD, Pradhan AD et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006; 113:2278-2284.
  7. Morrow DA, Wang Y, Croce K et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) Trial. Am. Heart J. 2008;155:49-55.
  8. Horvath I, Jia X, Johansson P et al. Pro-inflammatory S100A9 protein as a robust biomarker differentiating early stages of cognitive impairment in Alzheimer’s disease. ACS Chem Neurosci. 2016; 7 (1) : 34-9. doi: 10.1021/acschemneuro.5b00265. Epub 2015 Nov 12.
  9. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Reum. 2004; 50:3762-3771.
  10. Frosh M, Roth J. New insights in systemic juvenile idiopathic arthritis – from pathophysiology to treatment. Rheumatology (Oxford). 2008;47: 121-125.
  11. Damo SM, Kehl-Fie TE, Sugitani N et al. Molecular basis for manganese sequestration by calprotectin and roles in the innate immune response to invading bacterial pathogens. PNAS. 2003; 110 (10):3841-3846.
  12. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009; 9:162-174.
  13. Nacken W, Roth J, Sorg C, Kerkhoff C. S100A8/S100A9: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc. Res. Tech. 2003; 60: 569-580.
  14. Turovskaya O, Foell D, Sinha P et al. RAGE, carboxylated glycans and S100A8/S100A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008; 29: 6-14.
  15. Hiratsuka S, Watanabe A, Abutarani H, Maru Y. Tumor-related upregulation of chemoattractants and recruitments of myeloid cells predetermines lung metastases. Nat. Cell. Biol. 2006; 8:1369-1375.
  16. Ghavami S, Rashedi I, Dattilo B.M et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J. Leuoc. Biol. 2008; 83:1484-1492.
  17. Cheng P, Corzo CA, Luetekke N et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cell in cancer is regulated by S100A9 protein. J. Exp. Med. 2008; 205:2235-2249.
  18. Gebhardt C, Riehl A, Durchdewald M et al. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med. 2008; 205:275-285.
  19. Yanamandra K, Alexeyev O, Zamotin V, Srivastava V et al. Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate. Plos One. 2009; 4(5):e5562.
  20. Vogl T, Gharibyan A, Morozova-Roche L.A. Pro-inflammatory S100A8 and S100A9 proteins: self-assembly into multifunctional native and amyloid complexes. Int. J. Mol. Sci. 2012; 13:2893-2917; doi: 10.3390/ijms13032893.
  21. Viemann D, Strey A, Janning A et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood. 2005; 105: 2955-2962.
  22. Vogl T, Ludvig S, Goebeler M et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004;115 (13):4260-4268.
  23. Wang L, Luo H, Chen X, Jiang Y, Huang Q. Functional characterization of S100A8 and S100A9 in altering monolayer permeability of human umbilical endothelial cells. PLoS ONE. 2014; 9(3): e90472. doi: 10.1371 / journal. pone. 0090472.
  24. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage – associated molecular pattern molecules. J. Leukoc. Biol. 2007; 81:28-37.
  25. Foell D, Wittkowski H, Roth J. Mechanism of disease: a “DAMP” view of inflammatory arthritis. Nature Clinical Practice Rheumatology. 2007; 3 (7):382-390.
  26. Schafer B.W, Wicki R, Engelcamp D, Mattei M.G, Heizmann C.W. Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics. 1995; 25:638-643.
  27. Rammes A, Roth J, Goebeler M et al. Myeloid-related proteins (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J. Biol. Chem. 1997; 272:9496-9502.
  28. Sampson B, Fagerhol M.K, Sunderkorter C et al. Hyperzinkemia and hypercalprotectinemia: a new disorder of zink metabolism. Lancet. 2002; 360:1742-1745.
  29. Isidor B, Poignant S, Corradini N et al. Hyperzinkemia and hypercalprotectinemia: unsuccessful treatment with tacrolimus. Acta Paediatr. 2008; 98:410-412.
  30. Frosh M, Strey A, Vogl T et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and active endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Reum. 2000; 43:628-637.
  31. Robinson MJ, Tesseir P, Poulsom R, Hogg N. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparin sulfate glycosaminoglycans on endothelial cells. J. Biol. Chem. 2002; 277:3558-3665.
  32. Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the β2 integrin Mac-1 on neutrophils. J. Immunol. 1998; 160:1427-1435.
  33. Viemann D, Barczyk K, Vogl T et al. Myeloid-related proteins 8/14 impairs endothelial integrity and induces a caspase-dependent and –independent cell death program. Blood. 2007; 109: 2453-2460.
  34. Voelcker V, Gebhardt C, Averbeck M et al. Hyaluran fragments induce cytokine and metalloproteinase upregulation in human melanoma cells in part by signaling via TLR4. Exp. Dermatol. 2008; 17:100-107.
  35. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol. Pharm. Bull. 2003; 26(6):753-760.
  36. Ichikawa M, Williams R, Wang L et al. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol. Cancer Res. 2011; 9:133-148.
  37. Polonsky T.S, McClelland R.L, Jorgensen N.W et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010; 303 (16):1610-16.
  38. Eue I, Langer C, Eckardstein A, Sorg, C. Myeloid related protein (MRP) 14 expressing monocytes infiltrate atherosclerotic lesions of ApoE null mice.Atherosclerosis. 2000; 151:593–597.
  39. Ravasi T, Hsu K, Goyette J et al. Probing the S100 protein family through genomic and functional analysis Genomics. 2004; 84:10–22.
  40. Kerkhoff C, Eue I, Sorg C. The regulatory role of MRP8 (S100A8) and MRP14 (S100A9) in the transendothelial migration of human leukocytes. Pathobiology. 1999; 67:230–232.
  41. Yen T, Harrison C. A, Devery J. M et al. Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli
  42. Van den Bos, C, Roth, J, Koch, HG et al. Phosphorylation of MRP14, an S100 protein expressed during monocytic differentiation, modulates Ca(2+)-dependent translocation from cytoplasm to membranes and cytoskeleton.. 1996; 156:1247–1254.
  43. Raftery M. J, Yang Z, Valenzuela S. M, Geczy, C. L. Novel intra- and inter-molecular sulfinamide bonds in S100A8 produced by hypochlorite oxidation J. Biol. Chem. 2001; 276:33393–33401.

PREDICTION METHODS FOR RISK FACTORS OF CARDIAC RHYTHM AND CONDUCTION DISTURBANCES

Аuthors: E. Ts. Yasynska, Zh. A. Revenko

Pages: 195–200

Abstract

         

Using clinical and statistical analysis for patients with coronary heart disease (CHD), we selected patients with and without signs of arrhythmias and conduction of the heart. We also highlighted their risk factors and, based on these findings, developed a system of predicting the diseases. To identify patients with CHD risk factors of violations of rhythm and conductivity of heart was used prospective and retrospective surveillance methods. Based on the data regarding risk factors and anti-risk using the methods of Wald and Bayes developed a diagnostic prognostic table (map) in the form of predictive coefficients (PC) this informative weight of each trait.

Keywords: violations of rhythm and conductivity of heart, cardiovascular disease, system of prediction, risk and anti-risk factors, the prevalence of disorders of rhythm and conduction of the heart, prognostic indices, the methods of Wald and Bayes, informative weight of each trait, the observations map, the mathematical tools.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Gubler, EV. Vychislitelnye metody analiza s raspoznavaniya patologicheskikh protsessov [Computational methods of analysis and recognition of pathological processes] L: Meditsyna, 1976. 296 p.
  2. Thomson TF, McGee D, Davidsen M. [A cross – validation of risk – scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Frammingham Heart study]. Int. J. Epidemol. 2002: 817–822.
  3. Cohen M, Stinett SS, Weatherley BD. [Predictors of recurrent ischiemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy]. Am Heart J. – 2000. – Vol. 139. – P. 962–970.
  4. Disertori M, Dallafior D, Marini M. [Arrhythmia risk stratification based on etiological and anatomo-structural factors]. Ital Heart J. 2001; Vol. 2 (Suppl.12): 1265–1269.
  5. Elliott PM, Poloniecki J, Dickie S. [Sudden death in hypertrophic cardiomyopathy: identification of high risk patients]. J Am Coll Cardiol. 2000; Vol. 36: 2212–2218.
  6. Mark Estes NA, Homoud MK, Link MS. [Assessment of risk for sudden cardiac death]. Curr Probl Cardiol. 2002; Vol. 27 (6): 246–266.
  7. Moncrieff J, McGavigan AD, Dunn. [Arrhythmias, sudden death and syncope in hypertensive cardiovascular disease]. FG. Card Electrophysiol Rev. 2002; Vol. 6 (1-2): 36–41.
  8. Priori SG, Aliot E, Blomstrom-Lundqvist C. [Task force on sudden cardiac death of the European Society of cardiology]. European Heart Journal; 2001; Vol. 22: 1374–1450.
  9. Sabatine MS, McCabe CH, Morrow DA. [Identification of patients at high risk for death and cardiac ischemic events after hospital discharge]. Am Heart J. 2002; Vol. 143 (6): 966–970.

YEARLONG OBSERVATION OF FUNCTIONAL STATUS OF ATHLETES-SPRINTERS

Аuthors: Ye. L. Mikhalyuk, S. N. Malakhova, M. V. Didenko

Pages: 201-208

Abstract

         

Introduction. An important feature of sports medicine, unique to the athletes is the dynamics of the functional state of the body from the preparatory period to the competition; the athlete is in a state of good "fitness level".
The purpose was to study and compare HRV, central hemodynamics and PWC170 at athletes sprint qualification of the III-rd discharge to IMS obtained in the preparatory and competitive periods of training process.
Materials and methods of examination. A total of 35 runners who specialize in running at a distance of 100–200 m, the qualification of the III-rd discharge to IMS. The study of HRV and central hemodynamics was performed by the standard technique on the diagnostic complex "Cardio +”. Physical performance was measured on a bicycle ergometer with the calculation of submaximal test PWC170.
Results and discussion. General data on a group of sprinters athletes (n = 35) show that in the competitive compared to the preparatory period has been some strengthening of parasympathetic effects ANS transformation eukinetic in hypokinetic TC, lack of individuals with hyperkinetic TC significant increase PWC170/kg 11.22 % and IFS. Separate analysis of the athletes has demonstrated similar shifts in the competitive period with some advantages of high-class athletes. The correlations show that increasing PWC170/kg and the IFS is a decrease to CI values characteristic hypokinetic TC, while the high-class athletes, in addition to a decrease in before the values characteristic of the prevalence of parasympathetic ANS. Increased PWC170/kg and IFS helped to improve athletic performance and enhance their skills in the competitive period.
Conclusions. In competitive period compared to the preparatory period, in athletes-sprinters (n = 35), there has been some strengthening of parasympathetic effects ANS transformation eukinetic in hypokinetic TC and a significant increasing PWC170/kg to 11.22 %.
At high-class athletes (n = 26) in the competitive period occurred similar to that in the general group, shifts from the HRV and central hemodynamics, and a significant increased PWC170/kg to 10.24 %.
Athletes qualification of II–III discharge (n = 9) in the competitive period decreased parasympathetic ANS influences, prevalence athletes with eukinetic TC and the lack athletes with hyperkinetic TC and significant increase PWC170/kg to 11.93 %. PWC170/kg to 11.93 %.
As the physical performance of athletes to a reduction in the CI values corresponding hypokinetic TC, while the high-class athletes, in addition to reduced CI values characteristic of prevalence parasympathetic ANS.
Increase PWC170/kg and functional state in the competitive period helped to improve athletic performance and improve the skills of athletes.

Keywords: athletes of high class and low-skill, preparation and competition period, heart rate variability, central hemodynamics, physical performance, correlation.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Baevsky RM. [Analysis of heart rate variability in space medicine]. Human Physiology. 2002;28(2):70–82.
  2. Baevsky RM, Kirillov OI, Kletskin SZ.Matematicheskiy analiz izmeneniy serdechnogo ritma pri stresse[Mathematical analysis of changes in heart rate during stress]. M.: Nauka Publ., 1984, 225 p.
  3. Borovikov V. STATISTICA: iskusstvo analiza dannykh na komp'yutere. Dlya professionalov [STATISTICA: the art of data analysis on the computer. For professionals]. SPb.: Peter, 2001, 656 p.
  4. Gerasimov IG, Zaytsev IA, Tedeeva TA. [Individual reactions of the cardiovascular system in response to a physical impact]. Human Physiology. 1997;23(3):55–57.
  5. Zhemaytite TsI, Varonetskas GA, Sokolov EN. [Interaction of the parasympathetic and sympathetic autonomic nervous system in the regulation of heart rate]. Human Physiology. 1985;11(3):448–452.
  6. Zemtsovsky EV. Sportivnaya kardiologiya [Sports Cardiology]. SPb.: Hippocrates, 1995, 448 p.
  7. Karpman VL. [Functional diagnostics in sports medicine]. Clinical Medicine. 1980;6:3–7.
  8. Mikhalyuk EL. [Features research in sports medicine nowadays]. Zaporozhye Medical Journal. 2015;5(92):82–84.
  9. Mikhalyuk EL, Didenko MV, Malakhova SM. [Features autonomic regulation of heart rate, central hemodynamics and physical performance in short-distance runners]. Zaporozhye Medical Journal. 2014;2:64–68.
  10. Mutayeva ISh, Gizatullina ChA. [Way of individualization preparation of runners on short distances by taking into account the typological features of the circulation]. Pedagogical-psychological and medical-biological problems of physical training and sports. 2012;3(24):111–119.
  11. Oganov RG, Britov AN. [The differentiated approach to the development of physiological standards and its importance for preventive cardiology]. Cardiology. 1984;4:52–56.
  12. Mykhalyuk EL, Syvolap VV, Tkalich IV, inventors. Sposib otsinky funktsionalnoho stanu orhanizmu osib, shcho zaymayutsya fizychnoyu kulturoyu ta sportom[Assessment method of functional state of those engaged in physical culture and sport]. Ukrainian patent, no.36013, 2008.
  13. Pushkar YuT, Bolshov VM, Elizarova NA. [Determination of cardiac output by tetrapolar rheography and methodological possibilities]. Cardiology. 1977;7:85–90.
  14. Suslov FP, Sych VL, Shustin BN. Sovremennaya sistema sportivnoy podgotovki [The modern system of sports training]. M.: Publishing house "CAAM", 1995, 448 p.
  15. Karpman VL, Belotserkovsky ZB, Gudkov IV. Testirovaniye v sportivnoy meditsine [Testing in sports medicine]. M.: FIS, 1988, 208 p.
  16. [Heart rate variability: Standards of measurement, physiological interpretation and Clinical use]. Circulation. 1996;93(5):1043–1065.
  17. Kubiček WG, Patterson RP, Wetsol DA. [Impedance cardiography as a non-invasive method of monitoring function and other parameters of the cardiovascular system]. Ann. N.Y. Acad. Sci. 1970;170:724–732.

MODERN POSSIBILITIES OF ENDOSCOPIC SURGERY

Аuthors: R. M. Mykolayenko, D. G. Sumtsov, G. O. Sumtsov

Pages: 209–216

Abstract

         

A comparative analysis of the results of treatment of 4012 patients with various surgical, gynecological and urological pathologies was performed. Operated age of the patients is from 18 to 88 years. 1085 patients underwent endoscopic technique intervention and 454 patients experienced simultaneous operations. There was performed cholecystectomy in 243 (49.0 %) of 496 patients that underwent simultaneous operations and 83 (16.7 %) patients were with gynecological pathology. Only 76 (15.3 %) of the group were operated simultaneously on cholecystectomy and gynecological operation by video endoscopic method, but the majority (297 or 59.9 %) of patients were operated by means of an open surgical method, as the main problem in them was plastic hernia. 123 (24.8 %) patients were operated by means of an open surgical method only. Such simultaneous operations are possible and safe only after a thorough selection and preparedness of patients. Postoperative mortality was 0.02 % on 4012 operated patients; complications developed in 1.4 % of patients. There were no significant difference in the course of post operation period and frequency of complications after ordinary and simultaneous operations. The average hospital stay after laparoscopic operations was 2.6 days.
To select patients for simultaneous operations it is necessary to examine the gallbladder and cholecystic ducts before gynecological intervention; in case of surgical pathology in women the organs of small pelvis should be investigated. For wider application of simultaneous operations departments of operative gynecology should be placed in the surgical hospitals.

Keywords: laparoscopic and simultaneous operations, indications, advantages, complications.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Sookhih GT, Adamyan LV. Novyye tekhnologii v diagnostike i lechenii ginekologicheskikh zabolevaniy. [New technologies in diagnostics and treatment of gynecological diseases]. M., 2011; рр. 22–33.
  2. Zaporozhan VN, Таtarchuk ТF, Dronov АI [et al.]. [Single–plane operations at combination of gynaecological and surgical pathology]. Reproductive endocrinology. 2013; 3(11):7–16.
  3. Dronova VL, Dronov AI, Klyuchina EA [et al.]. [Simultaneous operations in combined surgical and gynecological diseases ]// Ukrainian Journal of Surgery. 2013; 2(21):143–150.
  4. Heshelin SO, Kashtalyan M. [Features of simultaneous laparoscopic operations in the abdominal surgery]. V National Conference on Innovation and Endoscopic Surgery in Gynecology.J Female doctor. 2008;6: 29–30.
  5. Khatsko VV, Shatalov AD, Dudin AM [et al.]. [Laparoscopic cholecystectomy: possible complications and prevention]. Ukrainian Journal of Surgery. 2012; 4(19): 62–64.
  6. Radzikhovskiy AP, Megndel NA, Tumanov KV. [Registration of anatomical variations of cystic artery and cystic duct location to prevent complications of laparoscopic cholecystectomy] Ukrainian Journal of Surgery. 2011; 3(12): 101–104.
  7. Vercellino G1, Erdemoglu E, Joe A, Hopfenmueller W [et al.]. Laparoscopic temporary clipping of uterine artery during laparoscopic myomectomy. Arch Gynecol Obstet. 2012; 286(5): 1181–1186.
  8. Baulina NV, Baulina EA. [Simultaneous operations in surgery and gynecology]. Journal of surgery named after I.I. Grekov. 2004; 163(2): 87–91.
  9. Fedorov AV, Kriger AG, Kolygin AV, Kochatov AV. [Simultaneous operations. Terminology (literature review and own suggestion)]. Surgery. 2011; 7: 72–76.
  10. Galimov OV, Ziganshyn DM, Tuysin SR [et al.]. [Treatment of patients with combined pathology of the pelvic organs with the use of laparoscopic technology]. Endoscopic surgery. 2012; 3: 25–28.
  11. Fedorov AV, Kolygin AV, Berelavichus SV, Kriger AG, Chernova TG, Goncharova NN, Solodkiy AV. [Assessment of predisposing risk factors for complications after combined operations]. Surgery. N.I. Pirogov Journal. . 2013; 4: 29–33.
  12. Nechitaylo MY, Zahriychuk MS, Bulyk II [at al.]. [Simultaneous laparoscopic surgery for gallstones and hernia of the abdominal wall]. Clinical Surgery. 2013; 5: 21–23.
  13. Sinno S, Shah S, Kenton K [et al]. A ssessing the safety and efficacy of combined abdominoplasty and gynecologic surgery. Ann. Plast. Surg. 2011; 67(3): 272–274.
  14. Wake BL, McCormack K, Fraser C [et al.]. Transabdominal pre-peritoneal (TAPP) vs totally extraperitoneal (TEP) laparoscopic techniques for inguinal hernia repair. Cochrane Database of Systematic Reviews. 2005; Issue 1. Art. No.: CD004703.
  15. Pchelnikov SS, Tenchurin ShA, Pashkov PP. [Cost-effectiveness of surgical interventions ]. Surgery. 1990; 11: 137–139.
  16. Strizheletsky VV, Rutenburg GM. [Economic efficiency of simultaneous operations in surgery and gynecology]. Moscow surgical journal. 2008; 1: 26–30.
  17. Ülker K, Anuk T, Bozkurt M and Karasu Y. Large bowel injuries during gynecological laparoscopy. World J Clin Cases. 2014; 2(12): 846–851.

FEATURES OF RESPONSE MECHANISM IN SKIN MANIFESTATIONS OF ALLERGIC REACTIONS IN INFANTS IN A LARGE INDUSTRIAL REGION

Аuthors: S. V. Vrublevskaya, G. A. Milko

Pages: 217–225

Abstract

         

According to the Ministry of Health of Ukraine (2013) there are 43 930 children with asthma registered only in Ukraine. The most numerous are the regions with unfavorable ecological situation: Donetsk, Zaporіzhzhya, Dnipropetrovsk, Kharkov and Kyiv regions. The increase of allergic diseases requires further study of its formation mechanisms and improvement of complex primary prevention.

Objective. To investigate the cause and spectrum of allergens in infants of Zaporіzhzhya region compared with data of Ukraine and Europe sources and to adapt complex methods of prevention in infants with risk of development of allergic reactions for Zaporіzhzhya region.

Materials and methods. We investigated the features of the mechanism of response in 623 children aged 0–3 years in a large industrial region (Zaporizhzhya, Odesa, Kherson regions) with clinical manifestations of cutaneous allergic symptoms. The level of specific IgE and IgG4 were determined by ELISA using analyzer "Immulyte 2000" and a set of reagents firm «Siemens» (Germany)." The data obtained were processed by mathematical statistics in Statistica for Windows.

Results. Among 623 infants with clinical manifestations of allergic reactions only 239 (38.36 %) had IgE-dependent type allergic reactions in infants. Among 323 (51.84 %) of infants the total and specific IgE, eosinophil cationic protein were within the age norm. It was found that among children with clinical manifestations of atopic diseases of the skin maximum hypersensibilization to food allergens was mainly due to chicken egg protein (34.48 %) and cow's milk (25 %) – in children younger than 2 years. It is lower in children after 3 years of life. Maximum exposure to inhaled allergens hypersensibilization is significantly increasing to 3 years mainly to epidermal allergens pets and household allergens (29 %).

Keywords: іnfants, hypersensitivity, allergens, IgE, IgG4.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Besh LV. [Prevention of allergic diseases in children as possible it is today?] Dytyachyj likar. 2009; 4: 7–13.
  2. Bousquet J, Khaltaev N, Cruz AA, et al.Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).; World Health Organization; GA(2)LEN; AllerGen. Allergy. 2008; Apr; 63 Suppl 86: 8–160.
  3. Volosovets OP.,Vrublevskaya S.V [The spectrum of sensitization in infants with IgE-dependent mechanism of disease in a large industrial area]. Zdorovye rebenka. 2015; 1 (60): 81–86.
  4. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report, an initiative of EAACI and AAAAI .Allergy.-2008; 63: 5–34.
  5. Eds. E. Isolauri, W.A. Walker, Allergic Diseases and Environment . Basel, 2004; Р.324.
  6. Kostromina VP., Stryzh V.O. [Etapy Stages of the prevention of allergic diseases in children]. Dytyachyj likar. 2010; 2:48–50.
  7. Kaznacheeva LF. i spivavt [Polymorphism of biotransformation of xenobiotics enzymes in children with atopic dermatitis]. Alerholohiya. 2002; 4:15–17.
  8. Martorell A.The predictive value of specific immunoglobulin E levels in serum for the outcome of the development of tolerance in cow’s milk allergy/ AllergolImmunopathol (Madr).-2008.-№ 36 (6).-S.325–330.
  9. Oxotnikova ОМ. [Prevention of allergies in children: current possibilities and prospects] Dytyachyj likar. 2011; 4: 26–35
  10. Pryluczkyj AS. i spivav. [Rates of specific IgE in children of different ages]. Laboratornaya dyagnostyka. 2013;3(65): 8–10.
  11. Ramesh S. Food Allergy Overview in Children. Clin. Rev. AllergyImmunol.2007; 8:23–33.
  12. Woods RK.Prevalence of food allergies in young adults and their relationship to asthma, nasal allergies, and eczema. Ann. AllergyAsthmaImmunol. 2002; 88: 183–189.

CARDIOMYOPATHY DUE TO OVEREXERTION

Аuthors: V. V. Bezuglaya

Pages: 226–236

Abstract

         

Despite the successes of sports cardiology, the scientific ideas of pathologic athletic heart are in a crisis state now in the domestic (Ukrainian) athletic-medical schools. This can be explained, on the one hand, by a growth in the frequencies of cardiac pathology and cardiac death in sport and, on the other hand, by the insufficient development of the scientific conception of pathologic athletic heart. The results of analysis of literature data testify to the necessity to distinguish the specific sports pathology of cardiovascular system. This is caused not only by the statistically high part of cardiac pathology in the general structure of illness and lethality in sport, but also by a number of specific features of the course of cardiac pathology in sportsmen. In other words, the separation of pathologic athletic heart as an individual nosologic unity is extremely urgent. The rejection of such pathology would mislead practicing cardiologists, who are forced to restrict themselves by the framework of generally accepted nosologies and sometimes to consider a clear pathology of sportsman’s heart as its physiological state. The slight development of the scientific conception of pathologic athletic heart hampers the study of the pathogenesis of diseases and the development of diagnostic criteria and therapeutic and prophylactic measures, which obviously does not favor a decrease in the morbidity of cardiovascular system and in the number of sudden cardiac deaths in sport.
Unfortunately, there exists no commonly accepted single term now for the definition of sports pathology of myocardium. In our opinion, in order to define the pathology of athletic heart, it is more expedient to use the words “cardiomyopathy due to physical overstress”, since this term indicates, first of all, the secondary character of damages of myocardium that arise at the noncorrespondence of the intensity and the volume of physical loads to the functional possibilities and the state of health of athletes. The clarification of etiopathogenous mechanisms of development of cardiomyopathy will favor the solution of one of the basic problems of applied sports medicine, namely, the treatment of a pathologic state of heart. Most researchers consider namely the physical overstress as the main reason for the appearance of myocardium's pathology in sportsmen. The data obtained for the last years allow us to assert that the physical loads are not the single reason, but a starting factor favoring the development of endogenous extracardiac disturbances, which favor the activation of pathologic processes in myocardium against the metabolism intensification background.
A specific feature of the pathology of a cardiovascular system in skilled sportsmen consists in that the dysfunction of myocardium mostly has no symptoms or is revealed only by a decrease in the resistance to physical loads. The real existence of cardiomyopathy in sportsmen is supported by distinctive changes in electrocardiograms. The ECG-equivalent of the given pathologic state in sportsmen is considered to be a violation of the processes of repolarization (a special attention should be paid to a horizontal displacement of the segment ST below the isoline by 1.0 mm with the transition to a negative wave T), as well as the presence of clinically significant disturbances of the rhythm of heart. It is very important that the majority of tragic events in sport is caused by namely a fatal arrhythmia.
In a number of cases, the cardiomyopathy due to a physical overstress can be manifested in a pathologic rearrangement of athletic hearts, which does not correspond to the directivity of the training process. First of all, this is related to the hypertrophy of myocardium, which is considered by most researchers as the necessary condition of the adaptation of sportsman’s heart. The hypertrophy of myocardium can be regarded as a version of physiological athletic heart, but only in the case where the myocardium thickness for the left ventricle is at most 12–13 mm in men and 11 mm in women. At the same time, the specific contribution of the myocardium hypertrophy to the general pattern of sudden deaths of sportsmen (with regard for the reasons concerning no heart) is already as high as 33 %. This is an indisputable proof of that the myocardium hypertrophy (of any etiology) is the direct reason for sudden deaths of sportsmen.
The results of analysis of the literature data indicate that the development of a myocardium hypertrophy in sportsmen ensures, to a certain extent, an enhancement of the functional possibilities of heart as a hemodynamical pump. At the same time, the disturbances arising in this case in the humoral regulation of the metabolism of myocardium, as well as changes in its blood supply and the intracardiac hemodynamics, not only decrease the efficiency of compensatory reactions, but lead to that the hypertrophy of myocardium on the subsequent stages of its development becomes a heavy factor for the activity of heart.

Keywords: athletic heart, cardiomyopathy, physical stress, hypertrophy, sudden cardiac death.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Platonov VN. Sistema podgotovki sportsmenov v olimpiyskom sporte. Obschaya teoriya i ee prakticheskie prilozheniya [The system of training athletes in Olympic sports. The general theory and its practical application]. – Kiev: Olympiyskaja Literatura Publ., 2004. 808p.
  2. Smolensky AV, Mikhailova AV. [Cardiac factors limiting physical performance of athletes]. Physical therapy and sport medicine. 2009;7(67):22–26.
  3. Graevskaja ND. Vliyanie sporta na serdechno-sosudistuyu sistemu[Influence of sports on the cardiovascular system]. – Moscow, 1975. 205 p.
  4. Platonov Vladimir. [Overtraining in Sport]. Science in Olympic sports. 2015; 1:19–34.
  5. Mikhailova AV, Smolensky AV. [Overvoltage athlete's heart]. Physiotherapy and Sports Medicine. 2009;12 (72):26–32.
  6. Schmied C, Borjesson M. Sudden cardiac death in athletes. J. Intern. Med. 2014;275(2):93–103.
  7. Angelini P, Vidovich MI, Lawless CE. Preventing sudden cardiac death in athletes: in search of evidence-based, cost-effective screening. Tex. Heart Inst. J. 2013;40(2):148–155.
  8. Eliot P, Andersson B, Arbustini E. Classification of the cardiomyopathies: a position statement from the ESC working group on myocardial and pericardial diseases. European heart journal. 2007;29(2):270–276.
  9. Sharma V, Srinivasan M, Sheehan DM, Ionescu A. Stress cardiomyopathy: case series and the review of literature. J. Emerg. Med. 2013;45(4) 95–98.
  10. Zemtsovsky E.V, Gavrilova EA. [Stress CMP or physical stress myocardial degeneration?]. Bulletinarrhythmology. 2002;(25)133.
  11. Aghajanian MG. [Electrocardiographic manifestations of chronic physical overexertion in athletes]. Human Physiology. 2005;31:60–64.
  12. Mikhailyuk EL. [Diagnosis of metabolic cardiomyopathy]. Physiotherapy and Sports Medicine. 2014;(1):40–49.
  13. Kovalenko VM, Lutai MI, Sіrenko YM Sertsevo-sudinnі zahvoryuvannya. Klasifіkatsіya, standarti dіagnostiki i lіkuvannya kardіologіchnih hvorih [The cardiovascular diseases. Classification, standards of diagnostics and treatment of cardiac patients]. – PP VMB: Association of Cardiologists of Ukraine, 2007. 128 p.
  14. Scharhag J,Löllgen H, Kindermann W. Competitive Sports and the Heart: Benefit or Risk? Dtsch Arztebl Int. 2013;110 (1-2):14–24.
  15. Perepecha, NB Rjadova SI. Kardiologiya: rukovodstvo dlya vrachey [Cardiology: A Guide for Physicians]. – St. Petersburg: SpetsLit. Publ.,2008. 432 p.
  16. Dembo AG, Zemtsovsky E V. Sportivnaya kardiologiya: Rukovodstvo dlya vrachey [Sport Cardiology: A Guide for Physicians]. Leningrad:Medicine, 1989. 464 p.
  17. Gavrilova EA. Sportivnoe serdtse. Stressornaya kardiomiopatiya [Athletic heart. Stress cardiomyopathy]. Moscow: Sovietsky Sport Publ., 2007. 198 p.
  18. Bloomer RJ, Cole B, Fisher-Wellman KH. Racial differences in postprandial oxidative stress with and without acute exercise. Int. J. Sport Nutrition&Exercise Metabolism. 2009;19(5)457−472.
  19. Dushanin SA, Pirogova EA. The diagnostic significance of the correlation between the effectiveness of subendocardial perfusion and the energy output compatible with the coronary reserve. Cor Vasa. 1982;24(1):27–57.
  20. Pristrom AM, Benhamed MA. [Oxidative stress and cardiovascular disease. Part 2]. Medicine. 2012;2 (24):19–24.
  21. Berlett BS, Levine RL. Designing antioxidant peptides. Redox Rep. 2014;19(2):80–86.
  22. Shilov AM, Knyazeva LV. Features drugs with metabolic oriented in the correction of ischemic syndromes. Attending physician. 2013;(7):59–64.
  23. Zaleski VN, Gavrilenko TI, Phylchenkov AA. [Apoptosis during ischemia and reperfusion].Doctoring. 2002;(1):8–15.
  24. Morton JP, Kayani AC, McArdle A, Drust В. The exercise-induced stress response of skeletal muscle, with specific emphasis on humans. Sports Med. 2009;39(8):643662.
  25. Dorofeeva E. [Adaptation mechanisms, early diagnosis and correction of violations of the highest achievements in sport: dissertation]. Dnepropetrovsk' Medical Academy, 2006. – 39 p.
  26. Rozhkova EA, Seyfulla RD, Wolkov SK. [Oxidative stress – universal pathogenetic mechanisms of the state of physical stress of an athlete: a review of the scientific literature]. Sports medicine. 2010;(1–2):29–36.
  27. Zinoviev OM, Preobrazensky VU, Sinitsyn VE, Mershin EA. [Cases of asymptomatic ECG changes at the professional athletes: in-depth medical examination]. Physical therapy and sports medicine. 2014;1(121):7–10.
  28. Smolensky AV, Mikhailova AV. [The main directions of development of the sports cardiology]. Science and Sports: Current Trends. 2013;(1):69–79.
  29. Pokan R, Hofmann P, von Duvillard S. [The heart rate turn point reliability and methodological aspects]. Medicine and Science in Sports and Exercise. 1999;(31)903–907.
  30. Belotserkovskyy ZB, Lubinа BG Serdechnaya deyatelnost i funktsyonalnaya podhotovlennost u sportsmenov [The cardiac activity and functional preparedness in athletes]. Moscow: Sovietsky Sport Publ., 2012. 548 p.
  31. Komoliatova VV, Makarov LM, Fedina NN, Kiseleva I.I. Microvolt T-wave alternans in adolescent eliteathletes. Kardiologiia. 2015;55(1):43–46.
  32. Serra-Grima R, Estorch M, Carrio I. Marked ventricular repolarization abnormalities in highly trained athletes electrocardiograms: clinical and prognostic implications. J. Am. Coll. Cardiol. 2000;36:1310–1316.
  33. Wu J, Stork TL, Perron AD, Brady WJ. The athlete's electrocardiogram. Am. J. Emergency Med. 2006;24:77–86.
  34. Cavallaro V, Petetta M, Betocchi B. Effects of sustained training on left ventricular structure and function in top level rowers. Eur. Heart. J. 1993;14:898–903.
  35. Pelliccia A,Di Paolo FM, QuattriniFM. Outcomes in athletes with marked ECG repolarization abnormalities. N. Engl. J. Med. 2008;358:152–161.
  36. Hart G. Exercise-induced cardiac hypertrophy: a substrate for sudden death in athletes? Exp. Physiol. 2003;88(5):639–644.
  37. Pelliccia A,Fernando MD, Di Paolo FM. Athletes with abnormal repolarization pattern and structurally normal heart can participate in competitive sport: A lifelong experience. J. Am.Coll. Cardiol. 2011;58(8):883–884.
  38. Cisse F, Ba L, Gueye A. Supervision of body composition and cardiovascular parameters in long sprint running athletes (400 m). Dakar Med. 2006;51(1):63–70.
  39. Wehrens XH, Chiang DY, Li N. Chronic exercise: a contributing factor to atrial fibrillation? J. Am. Coll .Cardiol. 2013;62(1):78–80.
  40. Baldesberger S, Bauersfeld U, Candinas R. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur. Heart. J. Cardiol. 2008;29(1):71–78.
  41. Rowland T. Is the ‘Athlete's Heart’ Arrhythmogenic?: Implications for Sudden Cardiac Death. Medicine & Science in Sports & Exercise. 2011;43:1552–1560.
  42. Grimsmo J, Grundvold I, Mæhlum S, Arnesen H. Echocardiographic evaluation of aged male cross country skiers. Scand. J. Med. & Science in Sports. 2011; 21:412–419.
  43. Franklin BA, Fletcher GF, Gordon NF. Cardiovascular evaluation of the athlete. Issues regarding performance, screening and sudden cardiac death. Sports-Med. 1997;24(8):97–119.
  44. Fragakis N, Koskinas KC, Vassilikos V. Arrhythmias in athletes: evidence-based strategies and challenges for diagnosis, management, and sports eligibility. Cardiol. Rev. 2013;21,(5):229–238.
  45. Kopylov AV, Ivanov GG, Janitorial VE. [Left ventricular hypertrophy: pathogenesis, diagnosis and prognosis]. Bulletin of Peoples' Friendship University, a series of Medicine. 2002;(3):106–130.
  46. Degtyareva EA, Zhdanova OI, Linde EV, Mukhanov OA, Kantemirova MG. [The problem of pathological transformation of the "athlete's heart" in young sportsmen and study the role of risk factors in adequate patronage]. Natural and engineering sciences. 2009;(6):237–242.
  47. Perrault H, Turcotte RA. Exercise-induced cardiac hypertrophy. Fact or fallacy? Sports-Med. 1994;17(5):288–308.
  48. Maron BJ, Carney KP, Lever HM. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J. Am. Cardiol. 2003;41(6):974–980.
  49. Sharma S, Maron BJ, Whyte G. Physiologic limits of left ventricular hypertrophy in elite junior athletes: relevance to differential diagnosis of athlete's heart and hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2006;40(8):1431–1436.
  50. Gavrilova EA, Zemtsovsky EV. [Sudden cardiac death and myocardial hypertrophy in athletes]. Bulletin arrhythmology. 2010;62(62):59–62.
  51. Foryst-Ludwig A, Kintscher U. Sex differences in exercise-induced cardiac hypertrophy. Pflugers Arch. 2013;465(5):731–737.
  52. Webner D, Duprey KM, Drezner J.A. Sudden cardiac arrest and death in United States marathons. Med. Sci. Sports Exerc. 2012;44(10):1843–1845.
  53. Sharma V, Srinivasan M, Sheehan DM, Ionescu A. Stress cardiomyopathy: case series and the review of literature. J. Emerg. Med. 2013;45(4):95–98.
  54. Linde EV, Akhmetov II, Astratenkova IV. [The role of hereditary factors in myocardial hypertrophy of the left ventricle in elite athletes]. International Journal of interventional cardioangiology. 2007;(13):49–54.
  55. Williams B. Angiotensin II and the pathophysiology of cardiovascular remodeling. Am. J. Cardiol. 2001;87(8A):10–17.
  56. Lindе EV,Akhmetov II, Ordzhonikidze ZG. [Clinical and genetic aspects of the formation of "pathological athlete's heart" among elite athletes]. Journal ofSports Science. 2009;(2):32–37.
  57. Gavrilova EA. [Doessportsmyocardium pathology?]. Sport medicine. 2014;(2):3–13.
  58. Abaturova OB, Kremneva LV, Shalaev SV. [Left ventricular hypertrophy: the role of hemodynamic and neurohormonal factors, the molecular mechanisms of cell development]. Medical science and practice. 2004;7:11–16.
  59. Mesihovic-Dinarevic S, Kulic M, Kreso A. Cardiovascular screening in young athletes in Sarajevo Canton. Bosn. J. Basic Med. Sci. 2010;3(8):227–233.
  60. Geselevich VA. [Cardiac arrhythmias and size of the left atrium in athletes]. Journal of Sports Medicine Russia. 1993;2(3):30–35.
  61. Palatini P, Scanavacca G, Bongiovi S. Prognostic significance of ventricular extrasystoles in healthy professional athletes: results of a 5-year follow-up. Cardiology. 1993; 82(4):286–293.
  62. Zhinkin NP, Sirotin AB, Kolegova NG. The incidence and the structure of rhythm and conduction disturbances in young athletes depending on the severity of left ventricular hypertrophy. Sports Medicine: Science and Practice. 2014;(2):83–84.
  63. Maskhulia L, Chabashvili N, Kakhabrishvili Z, Akhalkatsi V, Chutkerashvili T. [Electrocardiographic patterns and systolic and diastolic functions of the heart in the highly trained football players with increased left ventricular mas]. Georgian Med. News. 2006;132:76–80.
  64. Lefkos N, Boudonas G, Vassilicos V. Efthymiadis A. Influence of left ventricular hypertrophy on the diastolic performance in hypertensive patients and athletes. Acta Cardiol. 1993;48(5):507–514.
  65. Okin PM, Wachtell K, Gerdts E, Dahlöf B, Devereux RB. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure. J. Hypertens. 2014;32(12):2472–2478.

PECULIARITIES OF TREATMENT FOR BONE DISEASES IN WOMEN OF DIFFERENT AGE WITH DIFFUSE TOXIC GOITER

Аuthors: L. V. Gerasimenko, V. V. Khaziev

Pages: 237–245

Abstract

         

Introduction. Graves' disease in 60% of cases is followed by osteopenic bone disorders. Women are affected more than men. Moreover, bone disorders most often occur in women under the age of menopause. In Ukraine medical treatment (thyreostatic) or surgical treatment is most often used for treatment of Graves' disease.

Purpose. To determine the most effective methods of treatment for diffuse toxic goiter with correction of osteopenic complications in the women of different age – reproductive and menopausal.

Materials and methods. The patients with thypoid disorders were investigated – 36 of reproductive age and 29 menopausal, as well as healthy individuals (12 and 5, correspondingly). The examination included: ultrasound determination of the thyroid gland volume, mineral bone tissue density evaluation by dual-energy X-ray absorptiometry with reference criteria T- and Z-score calculation, and measurement of thyroid hormones and TSH with thyroid hormone immunoassay methods. Then, the patients were prescribed different treatments. All patients were administered Vitamin D3 and Calcium supplements for prevention. After that, two different age groups were given "Alpha-D3-Тeva" – medication for reproductive age; "Bonviva" (bisphosphonates group), "Bivalos" (Strontium ranelate) – for menopausal age. The preparations were taken for 12 months with a break for one month every 3 months of intake.

Results. Two other different age groups were treated surgically. It has been demonstrated that the surgical method of treatment of diffuse toxic goiter combined with anti-osteopenia medications leads to a more effective increase of the bone tissue mineral density values than medication method in attainment of euthyroid condition at the background of anti-osteopenia medications in both age groups of patients.

Keywords: reproductive age, menopause, osteopenia, osteoporosis, thyroid hormones, bone tissue density, medication treatment, surgical treatment.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Golovach YuI. [Evropeyskiy kongress po osteoporozu i osteoartritu: osmyslenie novykh dannykh]. Zdorov’ya Ukraїni. 2012;2(22):86–88.
  2. Osteoporoz / pod red. OM Lesnyak, LI Benevolenskoy. 2-e izd. Moskva: GEOTAR-Media, 2010. 272 p.
  3. GogakosAI, Duncan Bassett JH, Williams GR. Thyroid and bone. 2010;503(1):129–136.
  4. Vestergaard P, Mosekilde L. Hyperthy­roidism, bone mineral, and fracture risk- a meta-analysis. Thyroid. 2003;13:585593.
  5. Lee WY, Oh KW, Rhee EJ. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. 2006;37(4):511–516.
  6. Povoroznyuk VV, Grigorieva NV. Menopauzata. Kiev: Ukraїns'ka asotsіatsіya, 2002. 356 p.
  7. Jabbar S, Drury J, Fordham JN, Jabbar S. Osteoprotegerin, RANKL and bone turnoval in postmenopausal osteoporosis. J.Clin. 2011;64(4):354–357.
  8. Rozhinskaya LYa, Belaya ZhE. [Osteoporoz v praktike vracha-endokrinologa: sovremennye metody lecheniya]. Farmateka. 2010;3:39–45.
  9. Shuba NM. [Osteoporoz – aktual'naya problema XXI veka: sovremennoe predstavlenie o patogeneze i terapii]. Ukr. revmatol. zhurn. 2008;2:5-14.
  10. Atramentova LA, Utevskaya OM. Statisticheskie metody v biologii: uchebnik dlya stud. vyssh. uch. zav. Gorlovka:Vidavnitstvo Lіkhtar, 2008. 248 p.
  11. Beketova T. [Preparaty kal'tsiya v profilaktike i lechenii osteoporoza]. Vrach. 2008;10:71–74.
  12. Richy F, Schacht E, Bruyere O et al.Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif. Tissue Int. 2005;76:176–186.
  13. Gromova OA, Gupalo EM. [Rol' kal'tsiya i vitamina D v profilaktike osteoporoza v zerkale dokazatel'noy meditsiny: (lektsiya dlya prakt. vrachey)].Ginekologiya. 2008;10(5):61–70.
  14. Jabbar S, Drury J., Fordham JN. et al. Osteoprotegerin, RANKL and bone turnoval in postmenopausal osteoporosis. J.Clin.Pathol. 2011;64(4):354357.
  15. Amaresh Reddy P, Harinarayan CV, Alok Sachan et al. Bone disease in thyrotoxicosis. Indian J Med Res. 2012;135(3):277–286.
  16. Farr JN, Khosla S, Miyabara Y at al. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J. Clin. Endocrinol. Metab. 2013;98:249–257.
  17. Totoyan ES [Reproduktivnaya funktsiya jensthin pri patologii shitovidnoy jelezy]. AkusherstvoI1994;1:8–10.
  18. Ignacak A, Kasztelnik M, Sliwa T et al. Prolactin-not only lactotrophin. A "new" view of the "old" hormone. 2012;63(5):435–443.
  19. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr. Med. Res. Opin. 2004;20(8):1291–1300.
  20. Reginster JY, Seeman E, de Vemejoul MC et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocr. Metab. 2005;90:2816–2822.

GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) IN THE CEREBROSPINAL FLUID OF PATIENTS WITH ACUTE PNEUMOCOCCAL MENINGITIS

Аuthors: A. V. Sokhan

Pages: 246–250

Abstract

         

Introduction. Previous studies have indicated that the brain-specific astroglial protein GFAP is a biomarker candidate indicative of astroglial damage in patients with CNS deseases.It is proved that the increase in GFAP content in CSF indicates destruction of glial cells and breach the blood-brain barrier function. At the same time, diagnostic and prognostic significance GFAP changes in CSF of patients with acute neuroinfections not well understood, practically no data on GFAP levels in CSF of patients with acute bacterial meningitis.

Purpose. The aim of study was to evaluate the diagnostic and prognostic role of GFAP level in CSF of patients with pneumococcal meningitis in the course of the disease.

MaterialsandMethods. In patients with acute pneumococcal meningitis were identified GFAP levels in the CSF on admission and after 10–12 days of treatment. As a comparison group were examined 12 patients with respiratory infection and meningism. GFAP levels in the CSF of patients were determined by sandwich ELISA method using the "BioVendor" company test system, Czech Republic. 26 cases of acute pneumococcal meningitis were analyzed. Among them, 7 (26.92 %) showed disease of moderate severity, in 19 (73.08 %) – severe course. In 5 (19.23 %) patients, the disease ended lethally. Severity was mainly due to the development of cerebral edema, an infectious- toxic shock, neurological symptoms.

Discussion. It is shown that levels of glial fibrillary acidic protein in the acute period of the disease was significantly increased, depending on the severity of the disease. This indicator can be used to evaluate the severity and prognosis of the disease.

Keywords: pneumococcal meningitis, glial fibrillary acidic protein, CSF.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Brouwer MC, Tunkel AR, van de Beek D, et al. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clinical Microbiology Reviews. 2010;23:467–492.
  2. Giorgi R, Mantovani PJ, Ferroni E, Forcina A, Stanghellini E, Curtale F, and Borgia P. Incidence of bacterial meningitis (2001–2005) in Lazio, Italy: the results of integrated surveillance system. BMC Infectious Diseases. 2009;9:13.
  3. Mishal J, Embon A, Darawshe A, Kidon M, and Magen E. Community acquired acute bacterial meningitis in children and adults: an 11-year survey in a community hospital in Israel. European Journal of Internal Medicine. 2008;19:421–426.
  4. Van de Beek D, J de Gans, McIntyre P, and Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. The Lancet Infectious Diseases. 2004;4:139–143.
  5. Arda B, Sipahi OR, Atalay S, and Ulusoy S, et al. Pooled analysis of 2,408 cases of acute adult purulent meningitis from Turkey. Medical Principles and Practice. 2008;17:76–79.
  6. Thigpen MC, NE Rosenstein, CG Whitney, R Lynfield, et al.Bacterial meningitis in the United States – 1998–2003. 43-rd Annual Meeting Infectious Diseases Society of America. 2005; San Francisco, CA.
  7. Hsu, HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. New England Journal of Medicine. 2009;360:244–56.
  8. Nudelman Y. Bacterial meningitis: epidemiology, pathogenesis and management update. Drugs. 2009;Vol. 69, (18) 2577–2596.
  9. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2010;Jul 20; 75(3):208–16.
  10. Blinov DV [GFAP level in the serum after cerebral ischemia in the perinatal period]. Obstetrics, Gynecology and Reproduction. 2014;(1): 6–11.
  11. Brunkhorst R, Pfeilschifter W, Foerch C, et al. Astroglial Proteins as Diagnostic Markers of Acute Intracerebral Hemorrhage-Pathophysiological Background and Clinical Findings. Translational Stroke Research. 2010;1(4): 246–51.
  12. Christoph A. Mayer, Robert Brunkhorst, Marion Niessner, et al. Blood Levels of Glial Fibrillary Acidic Protein (GFAP) in Patients with Neurological Diseases. //PLoS One. 2013;8(4) Published online 2013 Apr 23.Retrieved from:http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0062101.
  13. Dhandapani MK, Mahesh VB, Brann DW, et al. Astrocytes and brain function. Tmplications for reproduction. Experimental Biology and Medicine. 2003; (228): P. 253–260.
  14. Gules I, Satoh M, Nanda A, Zhang JH, et al. Apoptosis, blood-brain barrier, and subarachnoid hemorrhage. Acta Neurochirurgica Supplement. 2003;V. 86., P. 483–487.
  15. Gormley S, RJ, Mcintosh A,Kerskens C, et al. Glial fibrillary acidic protein (GFAP) immunoreactivity correlates with cortical perfusion parameters determined by bolus tracking arterial spin labelling (bt-asl) magnetic resonance (MR) imaging in the wistar kyoto. Physiology & Behavior.2016;Apr 8. pii: s0031-9384(16)30142–1.
  16. Rahati M, Nozari M, Eslami H, Shabani M, Basiri M, et al. Effects of enriched environment on alterations in the prefrontal cortex GFAP- and S100B-immunopositive astrocytes and behavioral deficits in MK-801-treated rats. 2016;Apr 5. pii: S0306–4522(16)30052–5.
  17. Ren C, Kobeissy F, Alawieh A, Li N, Li N, Zibara K, et al. Assessment of Serum UCH-L1 and GFAP in acute stroke patients. Scientific Reports.2016;Apr 14;6:24588.

QUALITY OF LIFE IN PATIENTS WITH MIGRAINE TREATED WITH HIGH-FREQUENCY TRANSCRANIAL MAGNETIC STIMULATION

Аuthors: A. O. Bieliaiev

Pages: 251–257

Abstract

         

Introduction. Migraine is a common disease that affects the working age people, has physical, psychological and socio-economic consequences. Transcranial magnetic stimulation is a noninvasive and painless method of influence on the human nervous system. Quality of life is an important tool for monitoring health status of patient and different components of the health.
Purpose. To examine effectiveness of the treatment of migraine by high-frequency transcranial magnetic stimulation by determining quality of life.
Materials and methods. The study involved 30 patients with migraine who received high-frequency transcranial magnetic stimulation. Given the different data from the literature on the effectiveness of the different areas of the cerebral cortex, all patients were divided into two groups, depending on the area of stimulation: the dorsolateral prefrontal cortex and the motor cortex of the left hemisphere.
Results. After using TMS in patients with migraine biggest changes were vital activity (68.8 % in both groups), general health (58.4 % and 60 %, respectively). Also, significant changes were the role of emotional problems (50 %), role functioning (49.5 % and 53.3 %) and pain intensity (47.8 % and 46.1 %). Changes of physical and mental components also point to a significant improvement of the quality of life in both groups.
Conclusion. It is proved that usage of transcranial magnetic stimulation significantly improves the quality of life in patients with migraine, regardless of zone stimulation.

Keywords: migraine, transcranial magnetic stimulation, quality of life.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Mishchenko TS. [Migraine: epidemiology, diagnosis, treatment, prevention]. Zdorovie Ukrainy. 2010;2:7–9.
  2. Morozova OG. [Migraine: modern concepts of classification, diagnosis, therapy and prevention (Part I)]. Medicyna neotlozhnyh sostoyaniy. 2012;4:32–41.
  3. Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of the human motor cortex. Lancet.1985;i:1106–1107.
  4. Lefaucheur J, André-Obadia N, Antal A. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology. 2014;125:2150–2206.
  5. Rossi S, Hallett M, Rossini PM. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009;12:2008–2039.
  6. Yahenskyy AV, Sichkaruk. I.N. [Assessment of quality of life in modern medical practice]. Vnutrennyaya medicina. - 2007. - №3. – P. 27-30.
  7. Novik AA, Ionova TI. Rukovodstvo po issledovaniyu kachestva zhizni v medicine [Guidance on Quality of Life Research in medicine. 2nd edition]. Olma media group, 2007. 315 p.
  8. Malygina TY Slobodenyuk EV. [Assessment of the quality of life of patients with migraine when using triptans]. Dalnevostochnyi med.journal. 2013; 3: 138–143.
  9. Starikova, N.L. Erchenkova G.A., Minnebaev D.I. Preventive treatment of migraine. Lechashiy Vrach. - 2006. - № 9. - S. 90–91.
  10. Tomah NV, Gritsay AV, Yanovska TV. [Application of topiramate in the prophylactic treatment of migraine]. Ukrainskiy visnyk psihonevrologii. 2012;20(2):42–45.
  11. Anand KS, Sharma S. Quality of life in migraine. Clinical Overview. Special Issue: Migraine Drugs. Part II. 2007;68 (7):403–411.
  12. Terwindt GMFerrari MDTijhuis MGroenen SMPicavet HSLauner LJ. The impact of migraine on quality of life in the general population: the GEM study. Neurology. 2000;55(5):624–629.
  13. Clarke BM, Upton ARM, Kamath MV, Al-Harbi T, Castellanos CM. Transcranial magnetic stimulation for migraine:clinical effects. Headache Pain. 2006;7(5):341–346.
  14. Conforto AB, Amaro E. Jr, GonçalvesAL, Mercante JPGuendler VZFerreira JRKirschner CCPeres MF. Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine. 2013;34(6):464–472.
  15. Lipton RB, Dodick DW, Silberstein SD, Saper JRAurora SKPearlman SHFischell RERuppel PLGoadsby PJ.Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial.Lancet Neurol. 2010;9:373–9380.
  16. Misra UK, Kalita J, Bhoi SK. High-rate repetitive transcranial magnetic stimulation inmigraine prophylaxis: a randomized, placebo-controlled study. J Neurol. 2013;260:2793–2801.
  17. Likhachev SA. Golec YH. [Excitability of the cerebral cortex and the problem of selecting a protocol of transcranial magnetic stimulation in patients with multiple sclerosis]. Medicinskiy Journal. 2009; 1: 68–72.
  18. Instructions for use of data obtained using a questionnaire SF-36. [Internet resource] /accessmode: http://therapy.irkutsk.ru/doc/sf36a.pdf.
  19. Gandek B, Sinclair SJ, Kosinski M, Ware JE Jr. Psychometric Evaluation of the SF-36® Health Survey in Medicare Managed Care. Health Care Financ Rev. 2004;25 (4):5–25.
  20. Feschenko YI, Mostovoy YM, Babiychuk YV. [The procedure for the adaptation of international quality of life questionnaire in Ukraine. Experience with patients]. Ukr. Cardiology. Zh. 2002;3:911.

QUALITY OF LIFE DEPENDING ON THE STAGE OF CHRONIC KIDNEY DISEASE SECONDARY TO DIABETES TYPE 2

Аuthors: L. Z. Vons

Pages: 258–263

Abstract

         

The aim of our study was to investigate changes in quality of life of patients depending on the stage of chronic kidney disease (CKD), to assess the correlation and study the factors that affect the progression of CKD and affect the quality of life of patients. We studied impact of psychological and somatic disorders in patients with CKD secondary to diabetes type 2 in these components of quality of life. We studied gender features causing diabetes.

Materials and Methods. We observed a group of 120 patients with diabetes mellitus type 2, and DN of I–V stages and chronic kidney disease of I–V stages. Among the patients studied, 59 (49 %) were men and 61 (51 %) were women. Average age was 59.2 ± 0.9 years, mean duration of diabetes constituted 11.8 ± 0.7 years, mean duration of diabetic nephropathy – 2.5 ± 0.3 years, the average length of CKD – 2.7 ± 0.3. The average weight was 84.0 ± 1.3 kg. Stage CKD was defined by GFR determined by the formula CKD-EPI.

We established diagnosis by classification of diseases of the urinary system, which was adopted in 2005 by The II National Congress Nephrology, stage DN – according to the classification Mogensen C.E. in 1983. We used general clinical examination methods (serum creatinine and serum glucose, glycosylated hemoglobin, blood pressure measurements); quality of life using a questionnaire quality of life SF-36 [7].

The data were subjected to statistical research processing, used for this application package statistica (StartSoft USA, v.12). We used the method of nonparametric statistics: Pearson’s Chi-sguare test to determine the causes of diabetes in men and women; ANOVA using Fisher’s F-criteria to test the null hypothesis; Spearman rank correlation to determine the presence and strength of communication between the studied parameters. Statistically significant difference: p ˂ 0.05.

All patients were divided into 5 groups according to the stage of CKD. The first group included 26 patients with CKD stage I, the second group – 27 people with CKD stage II, the third group – 15 people with CKD stage III, the fourth group accordingly – 17 patients with CKD stage IV, and the fifth group – 35 people with CKD stage V.

Discussion. Positive correlation was found between age and stage of CKD patients, weight, duration of diabetes, duration of NAM, blood pressure. Inverse correlation was found between CKD and GFR, and fasting glucose levels and some indicators of quality of life: physical functioning (PF); Role-Physical (R p); pain (P); vitality (VT); emotional functioning (RE); psychological health (MH). But we did not find the correlation between CKD and general health (GH) and social functioning (SF).

During the investigation it was found that one of the causes of diabetes is stress, but there are also some gender features. Men have got problems related to work, while women – family problems.

In the patients, who have got progression of CKD, life quality is worse. Our data suggests that the correction of weight, blood pressure control and adequate treatment of hypertension have got not only positive effect on the progression of CKD, but also improves life quality in our patients.

Keywords: thyroid cancer, biomineralization, immunohistochemistry, markers, apoptosis, osteopontin.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Goh SG, Rusli BN, Khalid BA. Development and validation of the Asian Diabetes Quality of Life (AsianDQOL) Questionnaire. Diabetes Res Clin Pract. 2015 Feb 28. pii: S0168-8227(15)00106-0. doi: 10.1016/j.diabres.2015.02.009.
  2. Schieppati A. Chronic renal disease as a public health problem: epidemiologi, social and economic implications.Kidney Int.2005;98:7–10.
  3. GaidaievYuO. [Endocrinological state service of Ukraine and prospects of medical care to patients with endocrine disorders].International Journal of Endocrinology. 2006;2(4):9–14.
  4. Kamynskyi AV. [Diabetes: new insights and old misconceptions. Part 2. Prevention of type 2 diabetes].International Journal of Endocrinology. 2012;4:42–45.
  5. Kolesnyk M. [Endocrinology: Science and Practice]. Pharmacist. 2008;3:4–6.
  6. Krasiuk IV . [Influence chronic kidney disease progresses to quality of life]. Ukrainian Journal of Nephrology and Dialysis. 2015;2(46):37–41.
  7. Тhe world health organization quality of life (whoqol) – bref. Тhe world health organization, Geneva. 2004:6.
  8. Natsionalnyi reiestr khvorykh na khponich-nu khvorobu nyrok 2011 [National registry of patients with chronic kidney disease: 2011]. uklad. Kozliuk NI, Vladziievckaia GS, Kulyzkyiu MV.М. The Academy of Medical Sciences of Ukraine, Ministry of Health of Ukraine, State Institution "Institute of Nephrology AMS of Ukraine"; gol.red. Kolesnyk MO. К, 2012. 89 p.
  9. Novyk AA, Yonova TY. Pod red. akad. RAMN Shevchenko YuL. Rykovodstvo po yssledovanyiy kachestva zhyzny v medytsyne [Study Guide to quality of life in medicine]. 2nd: М. ОLМА Mediagroup Publ, 2007: pp. 18–19.
  10. Ostapova TS. [Changes in the quality of life in patients at different stages of chronic kidney disease in diabetes]. Bulletin pr. 2013;1,2(99):144–148.
  11. Dudar IO, Loboda OM, Korol LV, Alieksieieva VV. [Progression of chronic kidney disease and the role of oxidative stress in different stages of CKD]. Ukrainian Journal of Nephrology and Dialysis. 2012;2(34):18–24.
  12. Usova SV, Rodyonova TY. [Current approaches to evaluating the quality of life for patients with diabetes type 2]. Modern problems of science and education. 2014;6(6). From:http://www.science-education.ru/ru/article/view?id = 16610
  13. Yagenskyi AV. [Assessment of quality of life in modern medical practice]. Internal medicine.2007;3(3). From: http://www.mif-ua.com/archive/article/418.
  14. Yarmola TI. [Specifics of diabetic nephropathy in patients with secondary hypertension general practitioners - family medicine]. Ukrainian Journal of Nephrology and Dialysis.2015;3(47):34-39.

PECULIARITIES OF ADAPTATION IN TWINS NEONATAL INFANTS

Аuthors: I. N. Nikitina, A. B. Sukhariev, A. V. Boichuk, S. A. Smijan

Pages: 264–271

Abstract

         

Data collected in the obstetric hospital. The aim of the present study was to assess the peculiarities of adaptation of the newborn twins, depending on the type of zygosity. The peculiarities of neonatal adaptation 94 twins were studied. We studied obstetric history, course of pregnancy, delivery, the fetuses and during neonatal adaptation of the newborn. The state of the fetoplacental complex was carried out in 10–13, 16–22, 28–34 weeks of pregnancy. It is proved that the adaptation of newborns with multiple pregnancy depends on the type of placentation. It is established that monozygotic twins is a risk factor disadaptation syndromes. Children with monozygotic with twins in comparison with dizygotic have a higher incidence of respiratory distress syndrome and a greater tendency to jaundice, hemorrhagic syndrome, impaired hemolymphodrainage second and third degrees of severity. Physical development of twins also is determined by the type of zygosity. In the group monozygotic twins often have more severe variants of intrauterine growth retardation. The high frequency of asphyxia on a background of immaturity that leads to the development disadaptation syndromes in these children, the most frequent of which are hypoxic-ischemic lesion of the Central nervous system, disorders of thermoregulation and gastrointestinal reactions. The results of these studies allow us to recommend the type definition zygosity during pregnancy to develop medical tactics and prognosis. Further research and prevention of complications in multiple pregnancies allows developing a system of preventive measures to reduce perinatal morbidity and mortality. Recommendations made as a result of this study can be implemented in obstetric clinic. Further research is needed to determine further development of newborns.

Keywords: multiple pregnancy, neonatal adaptation, zygosity, fetal growth retardation.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Vdovichenko UP, Gojda NG, Kon'kov DG, Krasnov VV,  Lykyanovich OL, Makarchuk OM, Tkachenko AV, Chernov AV. Bagatoplidna vagitnist [Multiple pregnancy]. 2011. Retrievedfrom:http://motherandchild.org.ua/files/attachments/Multiple_pregnancy_Setup.zip.
  2. Baranov II, Tokova ZZ, Tadevosjan АА. [Perinatal outcomes in multiple births]. Obst. end gin. 2012;(1):98–102.
  3. Podzolkova NM, Skvorcova MU, Mel'nikova NI, Ostreikov IF. [Intrauterine infection state of the art]. Obst. end gin. 2009;(3):27–32.
  4. Egorova OA. [The course of pregnancy and delivery in women with a multiple pregnancy]. Vestnik Rosijskoj associacii akusherov-ginekologov. 2006;1(1): 36–37.
  5. Volodina NN. Nacionalnoe rukovodstvo po neonatologiy [National leadership in neonatology]. Moskow: Medecina Publisher, 2007, рр. 134–137.
  6. Knjazev JA, Senkevich VА, Bespalov JA. [During the early neonatal period and hormonal parameters in infants born of multiple pregnancies (twins)]. Pediatrija. 2009; 10(1):24–29.
  7. Dobrohotova UE, Ozerova RI, Mandrikina GA, Rora LC. [Some aspects of the etiology and pathogenesis of embryonic loss in the I trimester of gestation]. Vestnik Rosijskoj associacii akusherov-ginekologov. 2008;5:154–180.
  8. Ordjonikidze NV, Uchnickaya  ЕК. [Diagnosis of fetal infection]. Obst. end gin. 2008;(5):12–14.
  9. Sidel'nikova VМ. [Miscarriage modern view on the problem]. Obst. end gin. 2007;(5):24–27.
  10. Sidel'nikova VМ. [Prevention and treatment of threatening preterm delivery].Obst. end gin. 2008;(3):43–47.
  11. Almonte L, Davis M, Ward C, Brown D, Craparo F. Spontaneous and non - spontaneous twins: a comparasion study of preterm labor, preterm premature rupture of membranes, gestational age at delivery, maternal age, and len th of hospital stay. Twin Research and Human Genetics. 2012;15(2)170

INDICATIONS FOR THE FIRST ERYTHROCYTE TRANSFUSION IN PATIENTS WITH UPPER GASTRO¬INTESTINAL BLEEDINGS DEPENDING ON THE GENETIC CONSTITUTION

Аuthors: I. D. Duzhiy, S. M. Kobyletskyi, S. V. Kharchenko

Pages: 272–277

Abstract

         

Background. Today a personified approach may penetrate in a daily transfusion practice. Every patient with upper gastrointestinal bleeding should have a clear and individually selected indication for transfusion therapy.

Objective – to develop indications for the first erythrocyte transfusion for patients with upper gastrointestinal bleedings of different origin.

Materials and methods. A total of 10 patients with acute with upper gastrointestinal bleeding were studied in Sumy Regional Clinical Hospital and Sumy State University. The polymerase chain reaction method for ESR1/rs2234693 gene polymorphism of patients and the post hoc analysis were implemented.

Results. A new transfusion scheme was presented. The first erythrocyte transfusion was indicated to compensate ulcer and variceal bleedings, if diagnostics of haemostasis control, cardiovascular history and genotyping information were appropriately fixed and considered.

Conclusion. The first erythrocyte transfusion under the haemoglobinemia between ≤ 70 and 100 g/L may be individually effective when the clinical decision-making process for transfusion indication includes genotyping assessment. This strategy should be assessed in a future clinical trial.

Keywords: bleeding, transfusion, erythrocyte, gene polymorphism.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Carson JL, Carless PA, Hébert PC. Outcomes using lower vs higher hemoglobin thresholds for red blood cell transfusion. J.A.M.A. 2013 Jan 2;309(1):83–4.
  2. Mackenzie CF, Morrison C, Jaberi M, et al. Management of hemorrhagic shock when blood is not an option. J. Clin. Anesth. 2008 Nov;20(7):538–41. 18.
  3. Pollack MJ, Wong RC. The approach to patients with acute GI hemorrhage who cannot receive a blood transfusion. Gastrointest. Endosc. 2008 May;67(6):945–52.
  4. Chassot PG, Kern C, Ravussin P. [Hemorrhage and transfusion: the case of Jehovah's witnesses]. Rev. Med. Suisse. 2006 Nov 22;2(88):2674–6, 2678–9. [Article in French]
  5. Restellini S, Kherad O, Jairath V, et al. Red blood cell transfusion is associated with increased rebleeding in patients with nonvariceal upper gastrointestinal bleeding. Aliment. Pharmacol. Ther. 2013 Feb; 37(3):316–22.
  6. Order # 297 by The Ministry Health of Ukraine [“Towards implementation medical care standards and clinical protocols in surgery”], 02.04.2010. Retrieved from: https://www.moz.gov.ua/ua/portal/dn_20100402_297.html. Status on November 22, 2015: In law. [In Ukrainian].
  7. Thomassin L, Lerebours E. Quand et comment transfuser un malade au cours d’une hemorragie digestive haute ? La Lettre de l’Hepato-gastroenterologue 2014, Vol. XVII, 5 (septembre-octobre): 234–237. [Article in French].
  8. Fomin PD, Bereznytskyi YaC, Bojko VV, et al. [Advanced algorithms for diagnostics and management of acute gastrointestinal bleeding (methodical recommendations)]. The Ministry of Health, Kyiv, Ukraine, 2012, 108 с. Retrieved from:http://endoscopy.com.ua/assets/files/zkk.pdf. November 22, 2015. [In Ukrainian].
  9. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal. Engl. J. 2013 Jan 3;368(1):11–21. Erratum in: N Engl J Med. 2013 Jun 13;368(24):2341.
  10. Stupin VA, Baglaenko MV, Kan VI, et al. [Lethality after gastroduodenal ulcer bleeding]. Khirurgiia (Mosk.). 2013;(5):31–5. [Article in Russian].
  11. Ding J, Xu H, Yin X, et al. Estrogen receptor α gene PvuII polymorphism and coronary artery disease: a meta-analysis of 21 studies. J. Zhejiang Univ. Sci. B. 2014 Mar;15(3):243–55.
  12. Clapauch R, Mourão AF, Mecenas AS, et al. Endothelial function and insulin resistance in early postmenopausal women with cardiovascular risk factors: importance of ESR1 and NOS3 polymorphisms. PLoS One. 2014 Jul 31;9(7):e103444.
  13. Gao HH, Gao LB, Wen JM. Genetic polymorphisms in the ESR1 gene and cerebral infarction risk: a meta-analysis. DNA Cell Biol. 2014 Sep;33(9):605–15.
  14. Evans BJ, Burke W, Jarvik GP. The FDA and genomic tests--getting regulation right. N. Engl. J. Med. 2015 Jun 4;372(23):2258–64.
  15. Nguyen-Tat M, Hoffman A, Marquardt JU, et al. [Upper gastrointestinal bleeding and haemorrhagic shock at the end of the holidays: pre-hospital and in-hospital management of a gastrointestinal emergency]. Z. Gastroenterol. 2014 May;52(5):441–6. [Article in German]
  16. Sung JJ. “HOW I DO IT” Management of upper gastrointestinal bleeding. World Organisation of Digestive Endoscopy. Retrieved from: http://www.worldendo.org/assets/downloads/pdf/publications/how_i_doit/2008/omed_hid_upper%20gastrointestinal_bleeding.pdf. November 22, 2015.
  17. Halland M, Young M, Fitzgerald MN, et al. Characteristics and outcomes of upper gastrointestinal hemorrhage in a tertiary referral hospital. Dig. Dis. Sci. 2010 Dec;55(12):3430–5.

LYMPHOTROPIC THERAPY EXPIRIENCE IN DESTRUCTIVE FORMS OF ACUTE APPENDICITIS

Аuthors: V. V. Shimko, I. A. Pustoviy, M. M. Kuprienko

Pages: 278–282

Abstract

         

Topicality. Acute appendicitis occurs in 60–70 % of urgent surgery cases. Postoperative complications amount is 4–15 %, but mortality is at level of 0.1–10 %. Despite the advanced operations technology and a significant number of antibiotics that can be used during surgical treatment of destructive appendicitis forms, it doesn’t work to improve treatment results during last decade.
Materials and methods. It was researched about 48 results of acute destructive appendicitis surgical treatment using lymphotropic antibacterial therapy and retrospectively analyzed the same number of patients in whom cases the antibiotic therapy was carried out according to the standard method.
The results and discussion. The developed method of lymphotropic antibacterial therapy allows to prevent septic complications of ileocecal area in cases of main group patients. Among operated patients using standard antibiotic of therapy the iliac area infiltration occurred in 3 (6.3 %) cases, postoperative wound infiltrate – 8 (10.7 %), which confirms the possibility of regional lymph system readjustment.
Prospects for further research. To continue accumulation of clinical material and to examine the effectiveness of lymphotropic antibacterial therapy during acute appendicitis complications, including the appendiceal infiltrate.

Keywords: appendicitis, complications, antibiotic therapy.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Bezrodnyj BGh, Surmasheva OV, Iovica AV. [Choice of empirical antibiotic therapy in the surgical treatment of destructive forms of acute appendicitis]. Khirurghija Ukrajiny. 2011;(1):17–22.
  2. Duzhyj ID, Ponomarenko IV, Sydoruk MA. [First experience of lymphotropic antibacterial therapy at acute appendicitis]. Visnyk Sumsjkogho derzhavnogho universytetu. 2008; 2(2):46–48.
  3. Yvanjko OV, Kalyna RA. [Problems and directions of modern treatment of acute appendicitis]. Khirurghija Ukrajiny. 2014;3(51):100–104.
  4. Kapustjansjkyj DV, Kuznjecov AJa. [Reaction-response to inflammation in patients with acute appendicitis]. Aktualjni problemy suchasnoji medycyny : Visnyk Ukrajinsjkoji medychnoji stomatologhichnoji akademiji. 2008;8,(1/2):84–86.
  5. Kvit AD, Bochar VT. [Clinical and microbiological aspects of complicated acute appendicitis treatment]. Khirurghija Ukrajiny. 2015;(2):37–41.
  6. Matvijchuk BO, Mykhajlovych VV, Matvijchuk OB. [Problem of acute appendicitis in Ukraine]. Ljvivsjkyj medychnyj chasopys. 2002;8(4):103–109.
  7. Matvijchuk BO, Kvit AD, Terlecjkyj OM. [Bacterial factors and ways to optimize treatment program of patients with acute appendicitis]. Ukr. zhurn. khirurghiji. 2013;1(20):58–60.
  8. Duzhyj ID, Ponomarenko IV, inventors. Sposib profilaktyky ghninykh uskladnenj pry likuvanni khvorykh na ghostyj apendycyt [Method for preventing purulent complication in treatment of acute appendicitis]. Ukrainian patent, no.44648, 2009.
  9. Pronin VA, Boyko VV. Patologiya cherveobraznogo otrostka i appendektomiya [Pathology of the appendix and appendectomy]. Kharkiv: SІMs Publ., 2012. 304p.
  10. Voiculescu D, Palade R. Immunologic and bacteriologic study of severe acute appendicitis. Diagnostics and therapeutic considerations. Chіrurgia (Bucur). 2007;102(3):271–276.
  11. Lamps LW. Appendicitis and infections of the appendix. Semin. Diagn. Pathol. 2004;45(11):2181–2185.

SONOGRAPHIC EVALUATION OF THE VENOUS OBLITERATION PROCESS AFTER ENDOVENOUS LASER COAGULATION WITH DIFFERENT SOURCES AND MODES

Аuthors: Yu. V. Melekhovets, V. V. Leonov, O. K. Melekhovets, L. M. Skubyra

Pages: 283–292

Abstract

         

Introduction. The study highlights the issues sonographic evaluation of the vascular wall changes after endogenous laser coagulation (EVLT) of the lower extremities with a laser source with wavelength of 1470 nm, 989 nm and 445 nm.
Purpose. The aim of this study was the sonographic evaluation of the dynamics of vascular changes by using different EVLT sources and modes.
Materials and Methods. 142 patients with varicose disease S2-5sErAsPr divided into three groups depending on the mode EVLT using 940-nm, 1470-nm и 445-nm diode lasers. A duplex sonography (combination of the traditional ultrasound with colour and spectral Doppler) was performed to evaluate degree of reflux in junction of the common femoral vein with the great saphenous vein, make an assessment of the local haemodynamics, vein wall characteristic etc.
Results and discussion. Preoperative mapping and postoperative sonographic monitoring carried out on the basic criteria (the state of the vascular wall, assessment of the vein diameter, presence and duration of reflux, lack of vein compression sensor) on the 7-th and 28 day, 8-th and 12-th week, 6-th months and 1 year after EVLT. The main sonographic characteristic of the vein obliteration are: gradual obliteration with a progressive decrease in diameter, following by the complete disappearance of the vessel due to fibrosis. The final step is converting into hyperechoic fibrous cord.
Discussion. Rate of the complete vessel obliteration achievement is one of the most important prognostic markers of relapse prevention. The blood flow absence and vascular obliteration after EVLT with a wavelength of 1470 nm, 989 nm and 445 nm is determined after 1.5 month. Formation of fibrous cord in the same period and the lack of sonographic signs of direct damage to the vascular wall are revealed only when using EVLT 1470 nm.

Keywords: varicose veins, laser coagulation, EVLT, sonography.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Rabe E, Guex JJ, Puskas A,Scuderi AFernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. 2012; 31(2):105–15.
  2. Lanigan SW. Lasers in Dermatology. Springer, 2000. 111 р.
  3. Proebstle TM. Thermal damage of the inner vein wall during endovenous laser treatment: key role of energy absorption by intravascular blood. Dermatologic surgery. 2002; 28(7):596–600.
  4. Gillet JL, Perrin M, Allaert FA. Clinical presentation and venous severity scoring of patients with extended deep axial venous reflux. J Vasc Surg. 2006; 44:588–594.
  5. De Maeseneer. Managing Chronic Venous Disease. Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2015; 49, 678–737.
  6. Vasquez MA, Rabe E, McLaferty RB, Vasquez MA. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg. 2010; 52:1387–96.
  7. Martin Necas, Labropoulos N, Tiongson J, Tassiopoulos AK, Kang SS, Mansour MA, Baker WH. Duplex ultrasound in the assessment of lower extremity venous insufficiency. AJUM. 2010; 13 (4):37–45.
  8. Definition of venous reflux in lower extremity veins. J Vasc Surg. 2003; 38:793–798.
  9. Gillet JL. Duplex ultrasonography protocol for investigation of patients presenting with recurrent varicose veins after surgery. Phlebolymphology. 2009; 16(3):295–298.
  10. De Maeseneer M, Pichot O, Cavezzi A. Duplex ultrasound investigation of the veins of the lower limbs after treatment for varicose veins - UIP consensus document. Eur J Vasc Endovasc Surg. 2011; 42:89–102.

INDICATORS OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH AUTOIMMUNE THYROIDITIS CONCURRENT WITH ISCHEMIC HEART DISEASE

Аuthors: N. I. Chekalina

Pages: 293–302

Abstract

         

Introduction. The prevalence of autoimmune thyroiditis in Ukraine, which is the most common cause of hypothyroidism, in the past 10 years has increased by 68 %. Endothelial dysfunction formed under conditions of inflammation, today is regarded as the main pathogenic factor in atherosclerosis — morphological bases of coronary heart disease.

Purpose: To investigate the indicators of endothelial dysfunction in patients with autoimmune thyroiditis in combination with coronary heart disease.

Materials and methods. The study involved 75 people of both sexes aged 48 to 72 years: 55 patients with coronary heart disease (angina stable, II FC) were included to ​​the group of comparison, 20 persons (study group) had additionally autoimmune thyroiditis, euthyroidism, 5 of which had subclinical hypothyroidism previously treated by L-thyroxine. 15 volunteers made ​​up a group of healthy individuals. All participants in the study identified the blood circulating endothelial microparticles by identifying specific surface membrane molecules using monoclonal antibodies against the antigens CD32 and CD40 with cytofluometry. Like an additional marker that causes damage to the endothelium, blood level of tumour necrosis factor α by enzyme immunoassay was measured. Statistical analysis was performed using non-parametric test of Wilkokson for pairs data, correlations examined using nonparametric method of Spearman.

Results: The contents of microparticles CD32+CD40+ in peripheral blood were significantly higher in patients of study group than in patients of comparison group. This demonstrates the high level of endothelial dysfunction in chronic autoimmune inflammation. The number of microparticles CD32+CD40+ in patients of both groups was significantly higher than in healthy individuals. In cases of combination of coronary heart disease and autoimmune thyroiditis the level of tumour necrosis factor α was significantly higher than in the comparison group. We have identified a strong correlation between the number of circulating endothelial microparticles CD32+CD40+ and content of tumour necrosis factor α in peripheral blood. The sensitivity and specificity for the said pair of indices as markers of endothelial dysfunction was calculated.

Discussion. In cases of combination of autoimmune thyroiditis with coronary heart disease found significantly more pronounced signs of endothelial dysfunction than patients only with coronary heart disease, due to the influence of immune inflammation. Determination of the number of circulating endothelial microparticles by antigenic markers of endothelial activation CD32+CD40+ in combination with a tumor necrosis factor α in blood is highly informative method of verification of endothelial dysfunction in patients with autoimmune thyroiditis.

Keywords: endothelial dysfunction, autoimmune thyroiditis, coronary heart disease, circulating endothelial microparticles, systemic inflammation.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Potapov VN, Damdindorzh Davaasuren, Idrisov EM etal. [Analysis of endothelial dysfunction in patients with autoimmune thyroiditis, depending on the functional status of thyroid]. Med. Journal. 2011; 26(4), (Issue 2):172–176.
  2. Berezin AE, Kremser AA. [Impact of subclinical hypothyroidism on the pattern of circulating endothelial microparticles in patients with chronic heart failure patients]. Serce i sudini. 2015; 4: 23–30.
  3. Kaidashev І.P. [Sіrtuins — unіversal regulators cellfunction] Biopolymers and Cell. 2012; 28 (2): 93–102.
  4. Kovalenko VM, Kornatsky VM. Stres i hvoroby sistemy krovoobigu [Stress and cardiovascular diseases] – Kiev: SI "NSC"Institute of Cardiology named after Acad. MD Strazhesko", 2015. 354 p.
  5. Kravchenko V.І., Postol S. [Dynamics of the incidence of thyroid pathology in Ukraine].Mіzhnarodny endokrinologіchny magazine. 2011; 3 (35): 26–31.
  6. Kutsenko NL, Savchenko LG, Kaydasheva EI, et al. [Determination of circulating CD32+ CD40+-microparticles modification of degradation assessment of endothelial cells].Clinical Laboratory Dіagnostics. 2011; 7: 20–23.
  7. Romanovskaja GA, Akatova EV, Gorokhovskaya GN et.Farmateka. 2005; 9.Retrieved from:http://www.pharmateca.ru/ru/archive/article/6039.
  8. Petrishchev NN, Vasina LV, Vlasov TD. [Typical forms of endothelial dysfunction]. Cilium. 2007; 18: 31–36.
  9. Popov VV, Priyma NF, Kanavets NS. [Endothelial function in women with metabolic syndrome associated with autoimmune thyroiditis]. 2013; 4 (4): 61–64.
  10. Saprin AN, Kalinin EV. [Oxidative stress and its role in apoptosis mechanisms and the development of pathological processes]. Advances in biology and chemistry.1999; 39: 289–326.
  11. Treumova S.І. Boryak VP [The role of endothelial function in the pathogenesis of cardiovascular and bronchopulmonary pathology]. Visnik problem bіologіi i medicini. 2014; 3(109), (Issue 2): 306–309.
  12. Trybrat TA, Shut SV, Tretyakova LO. [Metabolic syndrome and thyroid dysfunction]. Visnik problem bіologіi i medicini. Bulletin problems of biology and medicine. 2015; 1(124), (Issue 2): P. 42–44.
  13. Karachentsov YU. [Fourteenth Danilevsky reading]. Chotirnadtsyatі Danilevskі chitannya. [Proceedings of the conference with international participation: achievements and prospects of experimental and clinical Endocrinology]. Kharkiv, 2015, 190 p.(In Ukrainian).
  14. Cairins CB, Panacek EA, Harken AN. Bench to bedside: Tumor necrosis factor–alpha: From inflammation resuscitation. Emerg. Med. 2000; 7: 930–941.
  15. Friedman MH, Henderson JM, Aukerman JA et al. Effect of periodic alterations in shear on vascular macromolecular uptake Biorheology. 2000; 37(4): 265–277.
  16. Chironi GN, Boulanger CM, Simon A Endothelial microparticles in diseases. Cell. Tissue Res. 2009; 335(1): 143–151.
  17. Gröger M, Sarmay G, Fiebiger E Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro. J. Immunol. 1996; 156(4): 1549–1556.
  18. Hiadovec J. Circulating endothelial cells as a sign of vessel wall lesions. Physiol. Bohemoslov. 1978; 27(2): 140–144.
  19. Lin PJ, Chang CH. Endothelium dysfunction in cardiovascular diseases. Changgeng Yi Xue Za Zhi. 1994; 17(3): 198–210.
  20. Pan L, Kreisle RA, Shi Y.Expression of endothelial cell IgG Fc receptors and markers on various cultures Chin Med J (Engl). 1999; 112(2): 157–161.
  21. Abid Hussein MN, Meesters EW, Osmanovic N etal. Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo. J Thromb. Haemost. 2003; 1(11): 2434–2443.
  22. Brogan PA, Shah V, Brachet C et al. Endothelial and platelet microparticles vasculitis of the young. Arthritis Rheum. 2004; 50(3): 927–936.
  23. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res. 2003; 59(2): 277–287.
  24. Meziani F, Tesse A, Andriantsitohaina R. Microparticles are vectors of paradoxical in-formation in vascular cells including the endothelium: role in health and diseases. Pharmacol. Rep. 2008; 60(1): 75–84.
  25. Loyer X, Vion AC, Tedgui A, Boulanger CM. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res. 2014; 114(2): 345–353.
  26. Berezin AE, Kruzliak P. [Circulating endothelial apoptotic microparticles as a new marker of cardiovascular risk (literature review)] Ukr. med. Chasopis. 2014; 5(103): 83–87.
  27. Кhaitov RM Imunologiya: structura i functiya immunnoy systemi: uchebnoe posobye [Immunology: structure and function of the immune system: a tutorial] – Moscow: GE-OTAR Media , 2013. 280 p.
  28. Hedrick CC. Lymphocytes in Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2015; 35(2): 253–257.
  29. Tomazic V, Rose NR, Shreffler DC. Autoimmune murine thyroiditis. IV. Localization of genetic control of the immune response. J Immunol. 1974;112(3):965–96
  30. Okayasu I. Transfer of experimental autoimmune thyroiditis to normal syngeneic mice by injection of mouse thyroglobulin-sensitized T lymphocytes after activation with concanavalin A. Clin. Immunol. Immunopathol. 1985; 36:101–109.
  31. Petersa AL, Stunzb LL, Bishopa GA. CD40 and autoimmunity: The dark side of a great activator. Seminars in Immunology. 2009; 21(5): 293–300.
  32. Foy TM, Aruffo A, Bajorath J etal. Immune regulation by CD40 and its ligand GP39. Annu. Rev. Immunol. 1996; 14:591–617.
  33. GrayanniotisG, MastersSR, NoelleRG. Suppression of murine thyroiditis via blockade of the CD40–CD40L interaction. Immunology. 1997; 90(3): 421–42
  34. Knolle PA. Cognate interaction between endothelial cells and T-cellsю Results Probl. Cell. Differ. 2006; 43: 151–173.
  35. Ying Maa, Shun-Xian Wanga, Yun Liub etal. Single nucleotide polymorphism of CD40 in the 5′-untranslated region is associated with ischemic stroke. Gene. 2013; 529(2): 257–261.
  36. Ming Wang, Yan Li, Wen Li et al. The CD40 Gene Polymorphism rs1883832 Is Associated with Risk of Acute Coronary Syndrome in a Chinese Case–Control Study. DNA and Cell Biology. 2011; 30(3): 173–178.
  37. Nedospasov SA. [Tumor necrosis factor and lymphotoxin : molecular genetics , regulation and physiological role] Genetics. 2003; 399(2): 207–214.
  38. Pekary AE, Levin SR, Johnson DG et al. Tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta 1 (TGF-beta1) inhibit the expression and activity of Na/K-ATPase in FRTL-5 rat thyroid cells J. InterferonCytokineRes. 1997; 17: 185-195.
  39. Herbein G, O′brein WA. Tumor necrosis factor (TNF) α and TNF receptors in viral pathogenesis. Proceedings of the Society for Experimental Biology and Medicine. 2000; 223: 241–257.

CHANGES OF LIPID METABOLISM IN CHRONIC HEART FAILURE DEPENDING ON THE DEGREE OF EXCESS WEIGHT

Аuthors: P. P. Bidzilya

Pages: 116–123

Abstract

         

Introduction. The body mass index (BMI) is a significant prognostic factor in patients with cardiovascular system diseases and in particular with CHF. According to the Framingham Study in subjects with increased BMI there was increased risk of developing CHF, 5 % in men, and 7 % in women for each unit of BMI. Though, that obesity is an important risk factor of diabetes mellitus type 2 and cardiovascular diseases, a high BMI may be associated with reduced mortality and better prognosis in CHF. This phenomenon is known as the "obesity paradox" or "reverse epidemiology". Violation of lipid metabolism is the most important pathogenetic links the development of atherosclerosis, coronary artery disease (CAD) and as a result CHF of ischemic genesis. In recent years an increasing number of works in which it is proved that in the conditions CHF it is the lower levels of lipid profile is associated with worse prognosis and low patient survival.

Thus, given the polarity of opinion regarding the "obesity paradox" and "lipids paradox" in CHF on the background of overweight and obesity, a small number of works which have studied the changes in lipid metabolism depending on the degree of excess weight, the chosen direction of research is timely and relevant.

Purpose. To study the changes of lipid metabolism in chronic CHF, depending on the degree of excess weight.

Materials and methods. The study included 211 patients with CHF I–III functional class on the background of normal, overweight and abdominal obesity of I–III degree. According to the objectives of the study, patients with CHF were divided into 5 groups depending on BMI. Group I included 26 patients with BMI 18.5–24.9 kg/m2 (normal weight). Group II included 67 patients with BMI 25–29.9 kg/m2 (overweight). Group III consisted of 59 subjects with BMI 30–34.9 kg/m2 (obesity of I degree). Group IV included 37 patients with BMI 35–39.9 kg/m2 (obesity of II degree). In the V group were 22 patients with BMI > 40 kg/m2 (obesity of III degree). The patients underwent general clinical and biochemical blood tests. Statistical processing of obtained data was performed using license program package Statistica (version 6.0).

Results. It was revealed that changes in lipid metabolism in CHF depending on degree of excess weight are characterized by increased levels of atherogenic and anti-atherogenic indices decrease simultaneously with the distribution of violations in patients with concomitant obesity.

Conclusion. Features of changes of lipid metabolism in CHF depending on the degree of excess weight were demonstrated.

Keywords: lipid metabolism, chronic heart failure, body mass index.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Daniels LB, Clopton P, Potocki M. et al: Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur. J. Heart. Fail. 2012 (14): 22–31.
  2. Mak K, Bhatt D. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur. Heart J. 2009 (30): 857–65.
  3. Kushnir YuS. Hemodynamika, funktsionalnyi stan endoteliu, nyrok ta trombotsytiv zalezhno vid indeksu masy tila pry khronichnii sertsevii nedoststnosti zi zberezhenoyu fraktsiyeyu vykydu livoho shlunochka [Hemodynamics, functional state of endothelium, kidneys, and platelets depending on the body mass index in chronic heart failure with preserved ejection fraction of the left ventricle]. Medical perspectives. 2014 (1): 29–36.
  4. Kenchaiah S, et al. Obesity and the risk of heart failure. New. Engl. J. Med. 2002 (347): 305–313.
  5. Hainer V, Aldhoon-Hainerova I. Obesity Paradox Does Exist. Diabetes Care. 2013 (36): 276–281.
  6. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J. Am. Coll. Cardiol. 2002 (39): 578–584.
  7. Kalantar-Zadeh K, Block G, Horwich T et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J. Am. Coll. Cardiol. 2004 (43): 1439–1444.
  8. Patterson C, Feightner JW, Garcia A et al. Diagnosis and treatment of dementia: 1. risk assessment and primary prevention of Alzheimer disease. CMAJ. 2008 (178): 548– 556.
  9. Tousoulis D, Charakida M, Stefanadi E et al. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol. 2007 (115): 144 –150.
  10. Bonilla-Palomas JL, Gámez-López AL, Moreno-Conde M et al. Total cholesterol levels predict in-hospital mortality in patients with acute heart failure aged 70 years or older. Rev. Esp. Geriatr. Gerontol. 2016 (13): 211-213.
  11. Kahn MR, Kosmas CE, Wagman G. Low-Density Lipoprotein Levels in Patients With Acute Heart Failure. Congest Heart Fail. 2013 (19): 85–91.
  12. Ying Chen, Xiao-Mei HE, Hong Meng. Relationship between lipids levels and right ventricular volume overload in congestive heart failure. Journal of Geriatric Cardiology. 2014 (11): 192–199.
  13. Voronkov LH et. al. Rekomendatsii po diahnostike i lecheniu khronicheskoi serdechnoi nedostatochnosti (2012) [Guidelines for the diagnosis and treatment of chronic heart failure (2012)]. Ukrainian cardiology journal. 2013 (1): 6–44.
  14. Chernyshov VA et al. Vzaemozviazok mizh okremymy spivvidnoshenniami i vyiavami syndromu insulinorezistentnosti [The relationship between the individual lipid ratios and manifestations of the syndrome of insulinresistance]. Ukrainian therapeutic journal. 2007 (3): 15–24.

INDICATORS OF PERIPHERAL BLOOD IN INFANTS WITH RESPIRATORY DISEASES DEPENDING ON THE LENGTH OF BREASTFEEDING

Аuthors: S. V. Popov, S. I. Bokova, D. V. Tetyura, A. A. Bilan, A. V. Tverezovsky, N. I. Kora

Pages: 310–315

Abstract

         

The severity of acute respiratory infections in children during the first 3–6 months of life and the development of complications may be due to the peculiarities of the immune system, its development after birth. Of particular influence on these processes, have particular power, in particular the presence and duration of breastfeeding. The objective was to study the features of the immune response of peripheral blood in conjunction with the duration of breast-feeding.

The study involved 60 children aged 1 to 3 years, who was being treated in the infectious department of children's hospital with a diagnosis of acute respiratory disease. They were divided according to age into 3 groups: 1 group included 20 children aged up to one year, 2 group – 20 children from year to 2 years and 3 group – 20 children aged 2 to 3 years. We analyzed the basic changes of the blood and the relationship between the absence / presence of breast-feeding for at least the first 6 months of life and gave the characteristics of the analysis of the deviations.

The results of blood tests showed some of basic changes of hematological indicators. It was found that the incidence of inflammatory changes and increases of toxicity grow with the age of the child and connected with a decrease in the frequency of breastfeeding. Feeding breast milk to the age of a year increases the probability of the improvements of the immune response in the form of higher levels mainly of neutrophils.

Keywords: acute respiratory infections, the immune system, breast-feeding.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Burk RF, Levander OA, Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, eds. Modern Nutrition in Health and Disease. 10th ed. Philadelphia: LippincottWilliams & Wilkins, 2006, pp. 312–325.
  2. Calder PC, Krauss–Etschmann S, de Jong EC, Dupont C, Frick JS, Frokiaer H, Heinrich J, Garn H, Koletzko S, Lack G, Mattelio G, Renz H, Sangild PT, Schrezenmeir J, Stulnig TM, Thymann T, Wold AE, Koletzko B. [Early nutrition and immunity – progress and perspectives]. Br. J. Nutr. 2006;96(4):774–90.
  3. Caplan M, Calder Ph, Prescott S. Scientific Review: The Role of Nutrients in Immune Function of Infants and Young Children Emerging Evidence for Long-chain Polyunsaturated Fatty Acids. Glenview, US, Mead Johnson & Company, 2007, 40 pp.
  4. Gerasimov SV, Bєlova GA, Pashuk GL, Senyuk ІM, Strekalіna YuІ, Tsapok AA. [New approaches to the treatment of acute respiratory viral infections in children]. Sovremennaya Pediatria. 2014;60(4):111–115.
  5. Gregory KE, Walker WA. [Immunologic Factors in Human Milk and Disease Prevention in the Preterm Infant]. Curr Pediatr Rep. 2013;1(4). doi: 10.1007/s40124-013-0028-2.
  6. Gold DR,Willwerth BM, Tantisira KG, et al. [Associations of cord blood fatty acids with lymphocyte proliferation, IL-13, and IFN-γ]. J Allergy Clin Immunol. 2006;117:931-938.
  7. Huang G, Yu D, Mao N, et al. [Viral etiology of acute respiratory infection in Gansu Province,China]. Plos One. 2013;8(5). Retrieved from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0064254.
  8. Kryuchko TO, Kushnereva TV, Ostapenko VP, Kolenko ІO. [Problem questions of keeping ambulatory children with acute respiratory viral infections]. Sovremennaya pediatriya. 2014;64(8):65–69.
  9. Li F, Jin X, Liu B, Zhuang W, Scalabrin D. [Follow-up formula consumption in 3- to 4- year-olds and respiratory infections: an RCT]. Pediatrics. 2014;133(6):1533-40. doi: 10.1542/peds.2013-3598. Epub 2014 May 19.
  10. Maidanik VG, Burlai VG, Gnateiko OZ. Propedevtichna pediatriya [Propaedeutic pediatrics]. Vіnnitsya: Nova Kniga, 2012, 880 p.
  11. Monto AS. [Epidemiology of viral respiratory infections]. Am J Med. 2002;112(suppl 6A):4–12.
  12. Parham P. The Immune System. 4rd edition. Garland Science, 2014, 532 p.
  13. Walker A. [Breast milk as the gold standard for protective nutrients]. J Pediatr. 2010;156 (2 Suppl):3-7.doi: 10.1016/j.jpeds.2009.11.021.
  14. Yaqoob P. [Fatty acids as gatekeepers of immune cell regulation]. Trends Immunol. 2003;24:639–645.

BURNOUT SYNDROME FORMATION AMONG MEDICAL WORKERS OF DIFFERENT SPECIALITIES

Аuthors: I. G. Mudrenko, О. О. Potapov, D. D. Sotnikov, D. Y. Sviridenko, V. S. Yurchenko

Pages: 316–323

Abstract

         

We studied regularities of burnout syndrome formation in three groups of medical workers: psychiatrists, internship doctors and hospital nurses of psychiatric establishments. The aim of the study is determination of syndrome manifestation depending on work experience on the position and gender in separate groups of respondents. The study was carried out according to Maslach Burnout Inventory, the value of three scales “Emotional exhaustion”, “Depersonalization”, “Reduction of professional achievements” was figured out. The total amount of respondents – 62 medical workers.
According to results of given data processing we determined that the hospital nurses have high level of all indices on a scale: “Emotional exhaustion”, “Depersonalization”, “Reduction of professional achievements”. The doctors show the average degree of depersonalization manifestation and reduction of professional achievements, in psychiatrists the high degree of emotional exhaustion is formed during professional activity. We established some regularity according to which we concluded that the work experience of paramedical worker immediately in contact with the mentally ill up to 10 years is maximal as for mental health preservation and prevention of emotional exhaustion. Henceforth, the signs of emotional and mental exhaustion are rapidly formed (p < 0,001). In psychiatrists and somatic practitioners such a tendency is absent, the work experience doesn’t influence on emotional exhaustion formation. Indices dynamics of depersonalization in medical workers didn’t reveal dependence on work experience. The signs of emotional non-responsiveness, indifference, formal fulfillment of duties without personal involvement and empathy are formed and acquire high degree in paramedical workers, and average one in doctors in some years after immediate contact with mentally ill patients and then keeps at the same level. Gender analysis showed that women in the result of chronic stress and overwork are more prone to reduction of professional achievements than men (p < 0.05).

Keywords: emotional burnout, emotional exhaustion, depersonalization, reduction of professional achievements, psychiatrists, doctors of somatic profile, nurses.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Vodopp'yanova NE. Profylaktyka y korrektsyya syndroma vыhoranyya [Prevention and correction of burnout]. Publiser of St. Petersburg University, 2011.160 p.
  2. Pshuk NG, Kaminska AO. [Some individual psychological predictors of professional disadaptation forming in surgery and therapeutic profile doctors]. Ukrayinskiy visnik psihonevrologiyi. 2014; 22 (78):84–87.
  3. Larentsova LY. [Psychological and psychopathological features of syndrome of emotional burnout among physicians of the clinical profile]. Rossyyskyy medytsynskyy zhurnal. 2008; 6:32–35.
  4. Pshuk NH, Kamins'ka AO. [Problema profesiynoyi dezadaptatsiyi likariv khirurhichnoho ta terapevtychnoho profilyu]. Arkhiv psykhiatriyi. 2013; 19(73):151–155.

EFFICIENCY OF INTEGRATED PLANT ADAPTOGEN FOR OPTIMIZING MENTAL CAPACITY IN OLDER SCHOOL AGE CHILDREN

Аuthors: T. Kaminska, E. Mukvich, L. Pinchuk

Pages: 324–334

Abstract

         

Introduction. Increased load school programs, forming long "school stress" lead to violations of the processes of memory, attention to stu-dents in need of periodic application not only preventive (prophylactic) and reconstruction and (medical) events.
Objective: to assess the effectiveness of herbal adaptogen extract of Ginkgo Biloba in the processes of mental performance, memory, think-ing ability to activate speed and increase the level of information pro-cesses in the high school age students. Material and methods. The study was conducted in 3 main groups of children and in 3 groups of comparison. Before and after the treatment a clinical examination of children by a neurologist and an ophthalmologist was carried out, dyna-mometry, measured blood pressure, heart rate were measured. Mental performance (stability, focus, precision and productivity) was deter-mined by tables of Anfimov. To evaluate the process of information processing we studied short and meaningful short-term visual memory. The nature and dynamics of vegetative changes measured in points for by AM Wayne.
Results. According to the parents and teachers children who received Ginkgo Biloba extract regularly for 3 months become calmer, less excit-ed and annoyed. The normalization of cortico-subcortical connections under the influence of treatment may be indicated by normalization of sleep. After the treatment pain of long bones disappeared that could be associated with the normalization of the microcirculation in the extremi-ties, as well as nosebleeds. The positive dynamics of existing symptoms in children surveyed contributed to the rapid decrease in body asthenia, fatigue and improvement of general condition, improved short-term visual memory.
Conclusions. After a course of treatment in children of all groups productivity and accuracy of the task significantly increased. Activation mental capacity occurred in all groups of children, regardless of their sex.

Keywords: Ginkgo Biloba extract, mental capacity, students.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Dovbonos TA, Sokolova NI. [On the bioequivalence of drugs ginkgo biloba]. Ukrainskyi nevrolohichnyi zhurnal. 2013;1:87-90.
  2. Markevych VE, Maidannyk VH, Zaitsev IE, Loboda AM, Tarasova IV. Morfofunktsionalni ta biokhimichni pokaznyky u ditei i doroslykh: navchalno-metodychnyi posibnyk dlia studentiv VNZ [Morphofunctional and biochemical parameters in children and adults: Textbook for students]. Sumy: Sumskyi derzhavnyi universytet, 2011. 303 p.
  3. Polka NS. [Improving medical and preventive maintenance of children in secondary schools - the requirement of time]. Dovkillia ta zdorovia. 2009;1:52-54.
  4. Ponomarova LI. [Features of formation of modern health students at different stages of learning]. Zdorove rebenka. 2014;2(53):35-38.
  5. Pohachevskiy AL. [Comparative monitoring of the functional state of the autonomic nervous system of adolescents]. Pediatriya. Zhurnal imeni Speranskogo GN. 2010; 3: 51-56.
  6. Serheta IV, Mostova OP, Panchuk OIu [ta in.]. [Mental Health and its place in the structure of prevention technologies in the context of the new European policy "Health - 2020"]. Skhidnoievropeiskyi zhurnal hromadskoho zdorov’ia. 2013;21(1):245–246.
  7. Serheta IV, Mostova OP, Tymoshchuk OV, Tekliuk RV, Lukina NIu, Makarov SIu. [Prognostic assessment process features of psycho physiological and mental adaptation of senior pupils to the conditions on the modern secondary schools based on statistical models]. Hihiiena naselenykh mists.2014;64:287-292.
  8. Serheta IV, Mostova OP. [Medical and social aspects of educational adaptation and health of pupils of school age]. Aktualni pytannia pediatrii, akusherstva ta hinekolohii. 2013; 2:20–22.
  9. Serheta IV, Mostova OP. [Peculiarities of psychophysiological adaptation process and the formation of physiological functions of the modern school pupils]. Aktualni problemy transportnoi medytsyny. 2013;32(2):84–93.
  10. Yoshitake T, Yoshitake S, Kehr J. The Ginkgo biloba extract EGb 761 and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br. J. Pharmacol. 2010; 159:. 659—668.

THE DISTRIBUTION OF ALLELIC VARIANTS LYS198ASN POLYMORPHISM OF THE ENDOTHELIN-1 GENE IN PATIENTS WITH ISCHEMIC ATHEROTHROMBOTIC STROKE WHO ARE SMOKERS AND NON-SMOKERS

Аuthors: T. B. Oleshko, D. Yu. Svyrydenko, V. Yu. Garbuzova

Pages: 335–340

Abstract

         

Introduction. Smoking is one of the main risk factors of cardiovascular diseases, including stroke. According to various studies the risk of blood stroke of smokers increases by 2–4 times, with the greatest risk for developing of ischemic atherothrombotic stroke (IAS). Smoking contributes to the development of atherosclerosis, arterial blood pressure increase and small cerebral vessel constriction as a result the cerebral blood supply becomes bad. One of the most priority field is to identify candidate genes involved in the pathogenic mechanisms of disease in patients with various risk factors, including smokers. That such is the gene endothelin-1, a powerful endogenous vasoconstrictor and a marker of endothelial dysfunction. It is known that smoking adversely affects the metabolism of the vascular wall.

Purpose. To study the distribution of allelic variants on gene polymorphism Lys198Asn endothelin-1 in patients with IAS in smokers and people who do not smoke.

Materials and Methods. For analysis venous blood of 170 patients with IAS (42.4 % women and 57.6 % men) aged 40 to 85 years (average age – 64.7 ± 0.73 years) who were on the records in the outpatient department Sumy clinical Hospital № 5 was used. The control group consisted of 124 patients (36.3 % women and 63.7 % men), average age was 76.7 ± 0.93 years. The groups did not differ in the ratio of two sexes (P = 0.294 for the χ²-test), but the average age of the first group (76.7 ± 0.93 years) was significantly higher than that of the second one (P < 0,001). Lys198Asn (rs5370) polymorphism of EDN-1 gene was determined by polymerase chain reaction, followed by restriction fragment length analysis of the allocation of them by electrophoresis in agarose gel. Statistical analysis was performed by using the software package SPSS-17. The value of P < 0.05 was considered as significant. Pathogenetic variant of stroke was determined according to the TOAST criteria. Ischemic stroke character was determined with the help of history and clinical information of the disease given by CT brain study.

Results. Among the persons who do not smoke there was no significant association between polymorphisms studied and the development of ischemic atherothrombotic stroke (P = 0.081). The difference frequencies of different variants of Lys198Asn polymorphism in patients that smoke who suffer from ischemic atherothrombotic stroke and patients of the control group is close to accurate (P = 0.052). Having used logistic regression method, the following results were received. Individuals Asn/Asn genotype carriers, who do not smoke revealed increased risk of ischemic atherothrombotic stroke by 3.4 times (P = 0.041; OR = 3.379). However, the risk of stroke of smokers was not statistically significant.

Conclusion. In persons who do not smoke and are Asn/Asn genotype carriers the risk of ischemic atherothrombotic stroke development is higher than in 3.4 times in comparison with homozygotes for the major allele.

Keywords: endothelin-1, gene polymorphism, ischemic stroke, smoking.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Oleshko TB, Garbuzova VYu, Ataman OV. [Zviazok Lys198Asn polimorfizmu hena endotelinu-1 z ishemichnym aterotrombotychnym insultom v osib iz normalnym ta pidvyshchenym arterialnym tyskom]. JClin. Exp. Med. Res. 2015;3(4):464–469.
  2. Eshchenko KN, Zhadan AV, Shustval NF. [Serdechno-sosudystaia systema y kurenye] Diabet i sertse.2013;4 (170):12–17.
  3. Dobrianska OV, Polka NS, Berdnyk OV, Yurchuk OM. [Dynamika poshyrenosti tiutiunopalinnia sered pidlitkiv] Hihiiena naselenykh mists. 2012;59:262–266.
  4. Pikas OB. Pro stan kurinnia tsyharok u suchasnykh umovakh, yoho vplyv na vynyknennia zakhvoriuvan v orhanizmi liudyny (ohliad literatury). Bukovynskyi medychnyi visnyk. 2015;Т19,4(76):227–230.
  5. Nykytyn YuP, Cymonova HY, Khoreva MA, Vorobev RY, Vorobeva EN, Shumakher HY, Osypova YV, Kuperman YB. [Rol dysfunktsyy еndotelyia v patoheneze ateroskleroza]. Ateroskleroz.2011;1:60–69.
  6. Girot M. [Smoking and stroke].  PresseMed. 2009;38(7–8):1120–1125.
  7. Neverovskyi DV. [Kurenye y yshemycheskyi ynsult]. Nevrolohyia, neiropsykhyatryia, psykhosomatyka. 2010;2(4):42–47.
  8. Zubayrova LD, Zubayrov DM. [Kurenye kak faktor ryska serdechno-sosudystykh zabolevanyi]. Kazanskyi medytsynskyi zhurnal. 2006;87(5):369–374.
  9. Rankinen T, Church T, Rice T, Markward N, Leon AS, Rao DC., Skinner JS, Blair SN and Bouchard C. [Effect of Endothelin 1 Genotype on Blood Pressure Is Dependent on Physical Activity or Fitness Levels]Hypertension.2007;50:1120–1125.
  10. Pakhomia NS, Uriasev OM, Shakhanov AV, [Rol polymorfyzmov nekotorykh henov v realyzatsyy arteryalnoi hypertenzyy ]. Zemskyi Vrach. 2014;3–4 (24):21–24.
  11. Feoktystova VS, Lypunova AS, Kolesnychenko MH, Leonova YA, Syrotkyna OV, Boldueva SA. [Polymorfyzm henov эndotelyalnoi NO-syntazy, endotelyna-1 y paraoksonazy-1 kak faktor ryska kardyalnoho syndroma X u zhenshchyn] Problemy zhenskoho zdorovia. 2012;3(7):24–29.
  12. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. [Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment]. Stroke. 1993;24:35−41.

IMMUNOHISTOCHEMICAL STUDY OF PAPILLARY THYROID CARCINOMA WITH BIOMINERALIZATION

Аuthors: A. V.  Rieznik, R. A. Moskalenko, A. M. Romanjuk

Pages: 341–351

Abstract

         

Introduction.Thyroid cancer (TC) is the most frequent malignant tumor of the endocrine system, which besides has a relatively indolent course. The increasing incidence of thyroid cancer is mainly due to papillary thyroid cancer (PTC).
The aim is immunohistochemical studies of tissue of papillary thyroid cancer in conditions of presence and absence of biomineralization phenomena.
Materials and methods. 30 samples of PTC with signs of biomineralization and 30 samples without PTC biomineralization were examined. All PTC patients with signs of pathological biomineralization were joined in I (first) group (30 people). Patients who had PTC without signs of mineralization were included to the II (second) group (30 people). Immunohistochemical studies of protein expression of Ki-67, p53, bax, bcl-2, osteopontin (OPN), matrix metalloproteinase 1 (MMP1), and vascular endothelial growth factor (VEGF) were conducted in PTC tissue of both groups.
Data processing was carried out with the help of applied statistical methods, using Microsoft Excel 2010 with the addition AtteStat 12.0.5. The research results were checked for normal distribution by Shapiro-Wilky test. Evaluation of statistical significance of results difference between groups of samples was performed using nonparametric Mann-Whitney test and parametric t-Student test. The results were considered statistically significant at the probability of 95 % (p < 0.05).
Results. The difference between the results of immunohistochemical studies of bax expression (p < 0.001), OPN (p < 0.001) and VEGF (p < 0.05) in groups of PTC samples with the presence and absence of biomineralization may indicate their participation in pathological biomineralization processes under the conditions of this pathology.
It was found out that the presence of biomineralization is combined with significantly higher levels of expression of bax in thyroid tissue of malignant tumor (p < 0.001). High expression of bax protein and low expression of its antagonist bcl-2 indicate the strengthening of apoptosis in tumor cells.
The presence of pathological biomineralization leads to significantly higher levels of expression of protein OPN (p < 0.001) in the PTC tissue. It is known that osteopontin is an acidic phosphoprotein that is expressed in mineralized tissues and inhibits hydroxyapatite formation by binding to the surface of the crystals. We can assume that hyperproduction of osteopontin in tumor cells is a factor counteracting PTC biomineralization.
There have been exceeded endothelial growth factor expression in the group of PTC samples with calcification in comparison with PTC group without it (p < 0.05). Since VEGF protein is responsible for restoring oxygen to tissues in the situation of insufficient blood circulation, it may indicate a higher level of hypoxia in the mineralized PTC tissues.
In general, assessing the impact of biomineralization on the course of PTC it can be said about its promotion to protective forces of the body, which is to enhance apoptosis in the tumor and to limit the spread and growth of tumors mechanically.

Keywords: thyroid cancer, biomineralization, immunohistochemistry, markers, apoptosis, osteopontin.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Ferlay J, Soerjomataram I, Dikshit R [et al.]. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136 (5):E359- E386.
  2. Ebina A, Sugitani I, Fujimoto Y et al. Risk-adapted management of papillary thyroid carcinoma according to our own risk-group classification system: Is thyroid lobectomy the treatment of choice for low-risk patients? Surgery. 2014;156:1579–1589.
  3. Davies L, Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002 JAMA. 2006; 295:2164–2167.
  4. Rieznik A, Smeyanov V, Tarasenko S et al. Analysis of the incidence of malignant thyroid tumors in Sumy region. J. Clin. Exp.Med. Res. 2015;3 (4): 609–617.
  5. Allred DC, Harvey JM, Berardo M, Clark GM.Prognostic and predictive factors in breast cancer by immunohistochemical analysis.. 1998; 11:155–168.
  6. Chipuk. JE, Moldoveanu T, Lambi L et al. The BCL-2 family reunion. Molecular Cell. 2010;37:299–310.
  7. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74 (4):609–19. doi:10.1016/0092-8674(93)90509-O. PMID 8358790.
  8. Zhu B, Suzuki K, Goldberg HA et al. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin / B. Zhu, // J Cell Physiol. 2004 Jan;198(1):155-67.
  9. Nemir M, DeVouge W, Mukherjee B. Normal rat kidney cells secrete both phosphorylated and nonphosphorylated forms of osteopontin showing different physiological properties. J. ., 2007;164:18202 – 18208.
  10. Mirza M, Shaughnessy E, Hurley J.K et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer. 2008; 122(1): 889–897. doi:10.1002/ijc.23204. PMID 17960616.
  11. Osinsky S. Vaupel P. Tumor microphysiology. Kyiv, Naukowa dumka. -2009. – 253 pp.
  12. Kerbel R.S. Tumor angiogenesis: past, present and near future. Carcinogenesis. 2000;21:505–515.
  13. Zhang C, Song X, Zhu M, Shi S. Association between MMP1-1607 1G>2G Polymorphism and Head and Neck Cancer Risk: A Meta-Analysis. PloS One. 2013; 2: 285–293.
  14. Fanjul-Fernández M, Folgueras A. R, Fueyo A.et al. Matrix metalloproteinase MMP-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses.J Biol Chem. 2013; 288: 14647-14656.
  15. Scatena M, Liaw L, Giachelli CM. Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007; 27:2302–2309.
  16. Ferrara N. The biology of VEGF and its receptors / N. Ferrara, H. P. Gerber, J. LeCouter. // Nature Medicine. – 2003. – № 9. – P. 669–676.